0,05. Доказательная медицина от магии до поисков бессмертия

Талантов Петр




Если специально не указано иное, все зарубежные материалы приводятся в переводе автора.


Часть первая

Rivers W. H. R. Medicine, Magic and Religion // British Medical Journal. 1915. November 20. Vol. 2. № 2864. P. 751–753.

Clayton D. H., Wolfe N. D. The adaptive significance of self-medication // Trends in Ecology and Evolution. 1993. Vol. 8. № 2. P. 60–63.

Singer M. S., Mace K. C., Bernays E. A. Self-medication as adaptive plasticity: increased ingestion of plant toxins by parasitized caterpillars // PLoS One. 2009. Vol. 4. № 3, e4796.

Kacsoh B. Z., Lynch Z. R., Mortimer N. T., Schlenke T. A. Fruit flies medicate offspring after seeing parasites // Science. 2013. Vol. 339. P. 947–950.

Milan N. F., Kacsoh B. Z., Schlenke T. A. Alcohol consumption as self-medication against blood-borne parasites in the fruit fly // Current Biology. 2012. Vol. 22. № 6. P. 488–493.

Bos N., Sundström L., Fuchs S., Freitak D. Ants medicate to fight disease // Evolution. 2015. November. Vol. 69. № 11. P. 2979–2984.

Furnas D. W., Sheikh M. A., Van Den Hombergh P., Froeling F. Traditional craniotomies of the Kisii tribe of Kenya // Annals of Plastic Surgery. 1986. January. Vol. 15. № 6. P. 538–556.

Ichida J. Proceedings of the 104th General Meeting of the American Society for Microbiology. reported / Birds use herbs to protect their nests. BJS, Science Blog. 2004.

Oxilia G., Peresani M., Romandini M., Matteucci C., Henry A. G., Schulz D. et al. Earliest evidence of dental caries manipulation in the Late Upper Palaeolithic // Scientific Reports. 2015. July 16. Vol. 5.

Owens B. Oldest tooth filling was made by an Ice Age dentist in Italy // New Scientist. 2017. April 7.

Walker A. A. Neolithic surgery // Archaeology. 1997. September/October. Vol. 50. № 5.

Johnson T. M. Premenstrual syndrome as a western culture-specific disorder // Culture, Medicine & Psychiatry. 1987. September. Vol. 11. № 3. P. 337–356.

Sonnedecker G. Kremers and Urdang’s history of pharmacy. 4th ed. Philadelphia: J. B. Lippincott, 1976.

Geller M. J. Ancient Babylonian medicine. Theory and practice. Chichester, West Sussex, U. K.: Wiley-Blackwell, 2010.

Nunn J. F. Ancient Egyptian Medicine. University of Oklahoma Press, 2002.

Moghaddam N., Mailler-Burch S., Kara L., Kanz F., Jackowski C., Lösch S. Survival after trepanation – Early cranial surgery from Late Iron Age Switzerland // International Journal of Paleopathology. 2015. December. Vol. 11. P. 56–65.

Keinan G. Effects of stress and tolerance of ambiguity on magical thinking // Journal of Personality and Social Psychology. 1994. July. Vol. 67. № 1. P. 48–55.

Mayer A. The monstrous birth: The theory of maternal impression and congenital malformations / Whitelaw W. A. (ed.). The Proceedings of the 10th Annual History of Medicine Days. Health Sciences Centre Calgary, 2001. P. 48–52.

Boyer P., Liénard P. Ritual behavior in obsessive and normal individuals: Moderating anxiety and reorganizing the flow of action // Current Directions in Psychological Science. 2008. Vol. 17. № 4. P. 291–294.

Peacock E. J., Wong P. T. P. Anticipatory stress: The relation of locus of control optimism and control appraisals to coping // Journal of Research in Personality. 1996. Vol. 30. P. 204–222.

Brincks A. M., Feaster D. J., Burns M. J., Mitrani V. B. The influence of health locus of control on the patient-provider relationship // Psychology, Health and Medicine. 2010. December. Vol. 15. № 6. P. 720–728.

Roddenberry A., Renk K. Locus of control and self-efficacy: potential mediators of stress, illness, and utilization of health services in college students // Child Psychiatry & Human Development. 2010. August. Vol. 41. № 4. P. 353–370.

Taylor S. E. Adjustment to threatening events: A theory of cognitive adaptation // American Psychologist. 1983. November. Vol. 38. № 11. P. 1161–1173.

Friedland N., Keinan G., Regev Y. Controlling the uncontrollable: effects of stress on illusory perceptions of controllability // Journal of Personality and Social Psychology. 1992. December. Vol. 63. № 6. P. 923–931.

Dannewitz H., Weatherly J. N. Investigating the illusion of control in mildly depressed and nondepressed individuals during video-poker play // The Journal of Psychology. 2007. May. Vol. 141. № 3. P. 307–319.

Tolin D. F., Worhunsky P., Maltby N. Sympathetic magic in contamination-related OCD // Journal of Behavior Therapy and Experimental Psychiatry. 2004. July. Vol. 35. № 2. P. 193–205.

Rozin P., Nemeroff C. J. Operation of the laws of sympathetic magic in disgust and other domains // Journal of Personality and Social Psychology. 1986.·April. Vol. 50. № 4. P. 703–712.

Nemeroff C. J., Rozin P. The makings of the magical mind: The nature and function of sympathetic magical thinking / K. S. Rosengren, C. N. Johnson, P. L. Harris (eds.). Imagining the impossible: Magical, scientific and religious thinking in children. Cambridge: Cambridge University Press. 2000. P. 1–34.

Bennett B. Doctrine of signatures: An explanation of medicinal plant discovery or dissemination of knowledge? // Economic Botany. Vol. 61. № 3. P. 246–255.

Hocking G. M. The doctrine of signatures // Journal of Crude Drug Research. Vol. 15. P. 198–200.

Hand W. D. Magical medicine: The folkloric component of medicine in the folk belief, custom, and ritual of the peoples of Europe and America. University of California Press, 1980.

Varner G. R. Menhirs, dolmen, and circles of stone: The folklore and magic of sacred stone. Algora Publishing, 2004.

Varner G. R. The history & use of amulets, charms and talismans. Lulu.com, 2008.

Black W. G. Folk medicine: A chapter in the history of culture. London, 1883.

Dalyell J. G. The darker superstitions of Scotland. London, 1835.

Peacock M. Executed Criminals and Folk-Medicine // Folklore. 1896. September. Vol. 7. № 3. P. 268–283.

On the Fast-Track to end AIDS by 2030: Focus on location and population. UNAIDS, 2015. November 24.

Agenda for zero discrimination in health-care settings. UNAIDS, 2017. February 15.

Hood B. M., Donnelly K., Leonards U., Bloom P. Implicit voodoo: electrodermal activity reveals a susceptibility to sympathetic magic // Journal of Cognition and Culture. 2010. Vol. 10. P. 391–399.

Rosengren K. S., Johnson C. N., Harris P. L. (eds.). Imagining the impossible: Magical, scientific, and religious thinking in children. Cambridge: Cambridge University Press, 2000.

Vamos M. Organ transplantation and magical thinking // Australian and New Zealand Journal of Psychiatry. 2010. October. Vol. 44. № 10. P. 883–887.

Inspector Y., Kutz I., Daniel D. Another person’s heart: Magical and rational thinking in the psychological adaptation to heart transplantation // The Israel Journal of Psychiatry and Related Sciences. 2004. Vol. 41. № 3. P. 161–173.

Parapia L. A. History of bloodletting by phlebotomy // British Journal of Haematology. 2008. November. Vol. 143. № 4. P. 490–495.

Ghosh S. K. Human cadaveric dissection: a historical account from ancient Greece to the modern era // Anatomy & cell biology. 2015. September. Vol. 48. № 3. P. 153–169. The aphorisme of Hippocrates (trans. into lat. and eng. by Thomas Coar). London: Longman, 1822.

Tasca C., Rapetti M., Carta M. G., Fadda B. Women and hysteria in the history of mental health // Clinical practice and epidemiology in mental health. 2012. Vol. 8. P. 110–119.

Gilman S. L., King H., Porter R., Rousseau G. S., Showalter E. Hysteria beyond Freud. University of California Press, 1993

Ganz J. Herophilus and vivisection: a re-appraisal // Istoriâ mediciny. 2014. Vol. 1. № 4. P. 5–12.

Bedford D. E. The ancient art of feeling the pulse // British Heart Journal. Vol. 13. № 4. P. 423–437.

Bensaude-Vincent B., Newman W. R. (eds.). The artificial and the natural: An evolving polarity. MIT Press, 2007.

Conrad L. I., Neve M., Nutton V., Porter R., Wear A. The western medical tradition: 800 BC to AD 1800. Vol. 1. Cambridge University Press, 1995.

Horstmanshoff H. F. J., Stol M. (eds.). Magic and rationality in ancient near eastern and Graeco-roman medicine. BRILL, 2004.

Shryock R. H. The history of quantification in medical science // Isis. 1961. June. Vol. 52. № 2. P. 215–237.

Von Staden H. (ed., trans.). Herophilus. The art of medicine in early Alexandria. Cambridge University Press, 1989.

Riese W. The structure of Galen’s diagnostic reasoning // Bulletin of the New York Academy of Medicine. 1968. July. Vol. 44. № 7. P. 778–791.

Schneeberg N. G. A twenty-first century perspective on the ancient art of bloodletting // Transactions & Studies of the College of Physicians of Philadelphia. 2002. December. Vol. 24. P. 157–185.

Brain P. Galen on bloodletting: A study of the origins, development and validity of his opinions, with a translation of the three works. Cambridge University Press, 1986.

Albinali Hajar H. A. Arab gulf traditional medicine-blood letting // Heart Views. 2004. Vol. 5. № 2. P. 178–183.

Jeaffreson J. C. A Book about Doctors. Library of Alexandria, 1858.

Slesak G., Inthalath S., Dittrich S., Paris D. H., Newton P. N. Leeches as further potential vectors for rickettsial infections // Proceedings of the National Academy of Sciences. 2015. December 1. Vol. 112. № 48.

Nehili M., Ilk C., Mehlhorn H., Ruhnau K., Dick W., Njayou M. Experiments on the possible role of leeches as vectors of animal and human pathogens: a light and electron microscopy study // Parasitology Research. 1994. May. Vol. 80. № 4. P. 277–290.

Stillman J. M. The contributions of Paracelsus to medical science and practice // The Monist. 1917. July. Vol. 27. № 3. P. 390–402.

Shackelford J. A philosophical path for Paracelsian medicine: The ideas, intellectual context, and influence of Petrus Severinus (1540/2–1602). Copenhagen: Museum Tusculanum Press, 2004.

Davis A. Paracelsus: a quincentennial assessment // Journal of the Royal Society of Medicine. 1993. November. Vol. 86. № 11. P. 653–656.

Frith J. Syphilis – its early history and treatment until penicillin and the debate on its origins // Journal of Military and Veterans’ Health. Vol. 20. № 4. P. 49–58.

Paxton F. S. Liturgy and Healing in an early Medieval Saint’s. Cult: the Mass in honore sancti Sigismundi for the Cure of Fevers // Traditio. 1994. Vol. 49. P. 23–43.

Rapport S., Wright H. (eds.). Great Adventures in Medicine. New York: The Dial Press, 1952.

Keinan G. The effects of stress and desire for control on superstitious behavior // Personality and Social Psychology Bulletin. 2002. January. Vol. 28. № 1. P. 102–108.

Pearce J. M. S. The Doctrine of Signatures // European Neurology. 2008. Vol. 60. № 1. P. 51–52.

Von Staden G. The discovery of the body: human dissection and its cultural contexts in ancient Greece // The Yale Journal of Biology and Medicine. 1992. Vol. 65. № 3. P. 223–241.

Abdullah S., Dar L. M., Rashid A., Tewari A. Hirudotherapy / Leech therapy: applications and indications in surgery // Archives of Clinical and Experimental Surgery. 2012. Vol. 1. № 3. Р. 172–180.


Часть вторая

Walter R., Robins B. (eds.) Voyage round the world in the years MDCCXL, I, II, III, IV by George Anson, Esq; Commander in Chief of a Squadron of His Majesty’s ships, sent upon an expedition to the South-Seas. London: John and Paul Knapton, 1748.

McDowell L. Vitamin history, the early years. First Edition Design Pub., 2013.

Gordon E. C. Scurvy and Anson’s voyage round the World: 1740–1744. An analysis of the Royal Navy’s worst outbreak // American Neptune. 1984. Summer. Vol. XLIV. № 3. P. 155–166.

Carpenter K. J. The history of scurvy and vitamin C. Cambridge University Press, 1988.

Harrison M. Scurvy on sea and land: political economy and natural history, c. 1780 – c. 1850 // Journal for Maritime Research. 2013. May. Vol. 15. № 1. P. 7–25.

Tröhler U. Quantification in British Medicine and Surgery 1750–1830, with special reference to its introduction into therapeutics. University College London, 1978.

Bartholomew M. James Lind and scurvy: a revaluation // Journal for Maritime Research. 2002. Vol. 4. № 1. P. 1–14.

Lind J. A treatise of the scurvy: in three parts, containing an inquiry into the nature, causes, and cure, of that disease, together with a critical and chronological view of what has been published on the subject. London: Printed for A. Millar in the Strand, 1757.

Macbride D. An historical account of a new method of treating the scurvy at sea: containing ten cases which shew that this destructive difeafe may be easily and effectually cured, without the aid of fresh vegetable diet. London: A. Millar and T. Cadell, 1767.

Mayberry J. A. Scurvy and vitamin C. Food and drug law. Harvard law school, 2004.

Stark W. The works of the late William Stark, M. D. consisting of clinical and anatomical observations, with experiments, dietetical and statical. London, 1788.

Finniss D. Placebo and pain: Chapter 1. Historical aspects of placebo analgesia. Elsevier Inc. Chapters, 2013.

Feinberg C. The placebo phenomenon // Harvard Magazine. 2013. January-February. P. 36–39.

Miller W. S. Elisha Perkins and his metallic tractors // Yale Journal of Biology and Medicine. 1935. October. Vol. 8. № 1. P. 41–57.

Perkins B. D. New cases of practice with Perkins’s patent metallic tractors, on the human body and on animals; but especially on infants and horses; chiefly from the clerical and medical professions; with a confutation of every attack upon the metallic practice, etc. London,1802.

Perkins B. D. The influence of metallic tractors on the human body, in removing various painful inflammatory diseases, such as rheumatism, pleurisy, some gouty, affections etc. etc. lately discovered by Dr Perkins, of North America; and demonstrated in a series of experiments and observations, by Professors Meigs, Woodward, Rogers, etc. By which the importance of the discovery is fully ascertained, and a new field of enquiry opened in the modern science of galvinism or animal electricity. London: J. Johnson & Ogilvy & Son, 1798.

Thomas T. G. Introductiry address, on the progress of medicine, and history of disease, delivered at the College of physicians and surgeons // The Richmond Medical Journal. 1866. Vol. 1. P. 238–257.

Booth C. C. John Haygarth, FRS: A physician of the Enlightenment. Philadelphia: American Philosophical Society, 2005.

Haygarth J. Of the imagination, as a cause and as a cure of disorder of the body: exemplified by fictitious tractors, and epidemical convulsions. Read to the Literary and Philosophical Society of Bath // The Monthly Review. 1801. Vol. 35. P. 420–422.

Jewson N. D. Medical knowledge and the patronage system in 18th century England // Sociology. 1974. September 1. Vol. 8. № 3. P. 369–385.

Krogsbøll L. T., Hróbjartsson A., Gøtzsche P. C. Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention // BMC Medical Research Methodology. 2009. Vol. 9. № 1. P. 1.

Hróbjartsson A., Kaptchuk T. J., Miller F. G. Placebo effect studies are susceptible to response bias and to other types of biases // Journal of Clinical Epidemiology. 2011. November. Vol. 64. № 11. P. 1223–1229.

Navratilova E., Porreca F. Reward and motivation in pain and pain relief // Nature Neuroscience. 2014. October. Vol. 17. № 10. P. 1304–1312.

Atlas L. Y., Wager T. D. How expectations shape pain // Neuroscience Letters. 2012. June 29. Vol. 520. № 2. P. 140–148.

Colloca L., Benedetti F. Placebo analgesia induced by social observational learning // Pain. 2009. Vol. 144. № 1–2. P. 28–34.

McMillan F. The placebo effect in animals // JAMA. 1999. October 1. Vol. 215. № 7. P. 992–999.

Hróbjartsson A., Gøtzsche P. C. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment // Journal of Internal Medicine. 2004. September. Vol. 256. № 2. P. 91–100.

Hróbjartsson A., Gøtzsche P. C. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment // The New England Journal of Medicine. 2001. June. Vol. 344. № 21. P. 1594–1602.

Tracey I. Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans // Nature Medicine. 2010. Vol. 16. № 11. P. 1277–1283.

Kelley J. M., Kraft-Todd G., Schapira L., Kossowsky J., Riess H. The influence of the patient-clinician relationship on healthcare outcomes: a systematic review and meta-analysis of randomized controlled trials // PLoS One. 2014. April. Vol. 9. № 4, e94207.

Bjørkedal E., Flaten M. A. Interaction between expectancies and drug effects: an experimental investigation of placebo analgesia with caffeine as an active placebo // Psychopharmacology. 2011. June. Vol. 215. № 3. P. 537–548.

Branthwaite A., Cooper P. Analgesic effects of branding in treatment of headaches // British Medical Journal. 1981. May 16. Vol. 282. P. 1576–1578.

Waber R. L., Shiv B., Carmon Z. et al. Commercial features of placebo and therapeutic efficacy // JAMA. 2008. Vol. 299. № 9. P. 1016–1017.

De Craen A. J., Roos P. J., De Vries A. L., Kleijnen J. Effect of colour of drugs: systematic review of perceived effect of drugs and of their effectiveness // BMJ. 1996. December 21. Vol. 313. № 7072. P. 1624–1626.

Goetz C. G., Leurgans S., Raman R., Stebbins G. T. Objective changes in motor function during placebo treatment in PD // Neurology. 2000. February 8. Vol. 54. № 3. P. 710–714.

Shetty N., Friedman J. H., Kieburtz K., Marshall F. J., Oakes D. The placebo response in Parkinson’s disease // Clinical Neuropharmacology. 1999. July-August. Vol. 22. № 4. P. 207–212.

Pollo A., Amanzio M., Arslanian A., Casadio C. Response expectancies in placebo analgesia and their clinical relevance // Pain. 2001. Vol. 93. № 1. P. 77–84.

Amanzio M., Benedetti F., Porro C. A., Palermo S., Cauda F. Activation likelihood estimation meta-analysis of brain correlates of placebo analgesia in human experimental pain // Human Brain Mapping. 2011. Vol. 34. № 3. P. 738–752.

De la Fuente-Fernández R., Lidstone S., Stoessl A. J. Placebo effect and dopamine release // Journal of Neural Transmission. 2006. Vol. 70 [Suppl]. P. 415–418.

Leuchter A. F., Cook I. A., Witte E. A., Morgan M., Abrams M. Changes in brain function of depressed subjects during treatment with placebo // American Journal of Psychiatry. 2002. January. Vol. 159. № 1. P. 122–129.

Peciña M., Stohler C. S., Zubieta J.-K. Neurobiology of placebo effects: expectations or learning? // Social Cognitive and Affective Neuroscience. 2014. Vol. 9. P. 1013–1021.

Benedetti F., Frisaldi E., Carlino E., Giudetti L., Pampallona A., Zibetti M. et al Teaching neurons to respond to placebos // The Journal of Physiology. 2016. Vol. 594. № 19. P. 5647–5660.

Mason P. Deconstructing endogenous pain modulation // Journal of Neurophysiology. 2005. Vol. 94. P. 1659–1663.

Wiech K., Ploner M., Tracey I. Neurocognitive aspects of pain perception // Trends in Cognitive Sciences. 2008. August. Vol. 12. № 8. P. 306–313.

Nederhof A. J. Methods of coping with social desirability bias: A review // European Journal of Social Psychology. 1985. Vol. 15. № 3. P. 263–280.

Kaptchuk T. J. Intentional ignorance: A history of blind assessment and placebo controls in medicine // Bulletin of the History of Medicine. 1998. Vol. 72. № 3. P. 389–433.

Lui F., Colloca L., Duzzi D., Anchisi D., Benedetti F., Porro C. A. Neural bases of conditioned placebo analgesia // Pain. 2010. December. Vol. 151. № 3. P. 816–824.

Wager T. D., Rilling J. K., Smith E. E., Sokolik A., Casey K. L., Davidson R. J. et al. Placebo-induced changes in fMRI in the anticipation and experience of pain // Science. 2004. February 20. Vol. 303. № 5661. P. 1162–1167.

Benedetti F., Amanzio M., Vighetti S., Asteggiano G. The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect // The Journal of Neuroscience. 2006. November 15. Vol. 26. № 46. P. 12014–12022.

Wager T. D. Expectations and anxiety as mediators of placebo effects in pain // Pain. 2005. June. Vol. 115. № 3. P. 225–226.

Kirsch I., Sapirstein G. Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication // Prevention & Treatment. 1998. June. Vol. 1. № 2. P. 1–18.

Atlas L. Y., Lindquist M. A. Brain mediators of predictive cue effects on perceived pain // The Journal of Neuroscience. 2010. September. Vol. 30. № 39. P. 12964–12977.

Kirsch I. Antidepressants and the Placebo Effect // Zeitschrift für Psychologie. 2014. Vol. 222. № 3. P. 128–134.

Pavlov I. P. Conditioned reflexes. Oxford: Milford, 1927.

Pavlov I. P. Lectures on conditioned reflexes. New York: International Publishers, 1928.

Allan L. G., Siegel S. A signal detection theory analysis of the placebo effect // Evaluation & the Health Professions. 2002. Vol. 25. P. 410–420.

Linde K., Fässler M., Meissner K. Placebo interventions, placebo effects and clinical practice // Philosophical transactions of the Royal Society of London. Biological sciences. 2011. June 27. Vol. 366. № 1572. P. 1905–1912.

Ruhé H. G., Mason N. S., Schene A. H. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies // Molecular Psychiatry. 2007. Vol. 12. P. 331–359.

Andrews G. Placebo response in depression: Bane of research, boon to therapy // The British Journal of Psychiatry. 2001. March. Vol. 178. № 3. P. 192–194.

Walsh B. T., Seidman S. N., Sysko R., Gould M. Placebo response in studies of major depression: variable, substantial, and growing // JAMA. 2002. April 10. Vol. 287. № 14. P. 1840–1847.

Tuttlea A. H., Tohyamaa S., Ramsayb T., Kimmelmanc J., Schweinhardtd P. et al. Increasing placebo responses over time in U. S. clinical trials of neuropathic pain // Pain. Vol. 156. № 12. P. 2616–2626.

Remple M. S., Bradenham C. H., Kao C. C., Charles P. D., Neimat J. S., Konrad P. E. Subthalamic nucleus neuronal firing rate increases with Parkinson’s disease progression // Movement Disorders. 2011. August 1. Vol. 26. № 9. P. 1657–1662.

De la Fuente-Fernández R., Ruth T. J., Sossi V., Schulzer M., Calne D. B., Stoessl A. J. Expectation and dopamine release: Mechanism of the placebo effect in Parkinson’s disease // Science. 2001. August 10. Vol. 293. № 5532. P. 1164–1166.

Benedetti F., Colloca L., Torre E., Lanotte M., Melcarne A., Pesare M. et al. Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus // Nature Neuroscience. 2004. Vol. 7. № 6. P. 587–588.

Benedetti F., Pollo A., Lopiano L., Lanotte M., Vighetti S., Rainero I. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses // The Journal of Neuroscience. 2003. May 15. Vol. 23. № 10. P. 4315–4323.

Pollo A., Torre E., Lopiano L., Rizzone M., Lanotte M., Cavanna A. et al. Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian patients // NeuroReport. 2002. August 7. Vol. 13. № 11. P. 1383–1386.

Woods S. C. Conditioned hypoglycemia: effect of vagotomy and pharmacological blockade // American Journal of Physiology. 1972. December. Vol. 223. № 6. P. 1424–1427.

Albring A., Wendt L., Benson S., Witzke O., Kribben A., Engler H., Schedlowski M. Placebo effects on the immune response in humans: the role of learning and expectation // PLoS One. 2012. Vol. 7. № 11, e49477.

Booth R. J., Petrie K. J., Brook R. J. Conditioning allergic skin responses in humans: a controlled study // Psychosomatic Medicine. 1995. September-October. Vol. 57. № 5. P. 492–495.

McKenzie J. N. The production of the so-called “rose-cold” by means of an artificial rose // American Journal of the Medical Sciences. 1896. Vol. 91. P. 45–57.

Mityushov M. I. Conditioned reflex secretion of insulin // Zhurnal vysshei nervnoi deiatelnosti imeni I. P. Pavlova 1954. March. Vol. 4. № 2. P. 206–212.

Siegel S. Explanatory mechanisms for placebo effects: Pavlovian conditioning / The Science of the Placebo. Toward an Interdisciplinary Research Agenda (eds. Guess, H. A., Kleinman, A., Kusek, J. W. et al). London: BMJ Books, 2002. P. 133–157.

Stanton M. E., Levine S. Pavlovian conditioning of endocrine responses / Ader R., Weiner H., Baum A. (eds.) Experimental foundations of behavioral medicine: conditioning approaches. Lawrence Erlbaum Assoc, Hillsdale,1988. P. 25–46.

Bykov K. M. The cerebral cortex and internal organs. New York: Chemical publ. co., 1957.

McQuaid E. L., Fritz G. K., Nassau J. H., Lilly M. K., Mansell A., Klein R. B. Stress and airways resistance in children with asthma // Journal of psychosomatic research. 2000. October. Vol. 49. № 4. P. 239–245.

Liu L. Y., Coe C. L., Swenson C. A., Kelly E. A., Kita H., Busse W. W. School examinations enhance airway inflammation to antigen challenge // American Journal of Respiratory and Critical Care Medicine. 2002. Vol. 165. P. 1062–1067.

Sandberg S., Jarvenpaa S., Penttinen A., Paton J. Y., McCann D. C. Asthma exacerbations in children immediately following stressful life events: a Cox’s hierarchical regression // Thorax. 2004. Vol. 59. P. 1046–1051.

Chen E., Hanson M. D., Paterson L. Q., Griffin M. J., Walker H. A., Miller G. E. Socioeconomic status and inflammatory process in childhood asthma: The role of psychological stress // Journal of Allergy and Clinical Immunology. 2006. Vol. 117. P. 1014–1020.

Lee P. C., Jawad M. S., Hull J. D., West W. H. L., Shaw K., Eccles R. The antitussive effect of placebo treatment on cough associated with acute upper respiratory infection // Psychosomatic Medicine. 2005. March-April. Vol. 67. № 2. P. 314–317.

Benedetti F., Maggi G., Lopiano L., Lanotte M., Rainero I. et al. Open versus hidden medical treatment: the patient’s knowledge about a therapy affects the therapy outcome // Prevention & Treatment. 2003. Vol. 6. № 1.

Reynolds D. V. Surgery in the rat during electrical analgesia induced by focal brain stimulation // Science. 1969. April 25. Vol. 164. № 3878. P. 444–445.

Willer J. C., Albe-Fessard D. Electrophysiological evidence for a release of endogenous opiates in stress-induced analgesia in man // Brain Research. 1980. October 6. Vol. 198. № 2. P. 419–426.

Terman G. W., Morgan M. J., Liebeskind J. C. Opioid and non-opioid stress analgesia from cold water swim: importance of stress severity // Brain Research. 1986. April 30. Vol. 372. № 1. P. 161–171.

Summerfield C., De Lange F. P. Expectation in perceptual decision making: neural and computational mechanisms // Nature Reviews Neuroscience. 2014. Vol. 15. P. 745–756.

Guerraz M., Day B. L. Expectation and the vestibular control of balance // Journal of cognitive neuroscience. 2005. March. Vol. 17. № 3. P. 463–469.

Babel M., Russell J. Expectations and speech intelligibility // The Journal of the Acoustical Society of America. 2015. May. Vol. 137. № 5. P. 2823–2833.

Koyama T., McHaffie J. G., Laurienti P. J., Coghill R. The subjective experience of pain: where expectations become reality // Proceedings of the National Academy of Sciences. 2005. September. Vol. 102. № 36. P. 12950–12955.

McClure S. M., Li J., Tomlin D., Cypert K. S., Montague L. M, Montague P. R. Neural correlates of behavioral preference for culturally familiar drinks // Neuron. 2004. Vol. 44. № 2. P. 379–387.

Melzack R., Scott T. H. The effects of early experience on the response to pain // Journal of Comparative and Physiological Psychology. 1957. Vol. 50. № 2. P. 155–161.

Keltner J., Furst A. J., Fan C., Redfern R. Isolating the modulatory effect of expectation on pain transmission: A functional magnetic resonance imaging study // The Journal of Neuroscience. 2006. May. Vol. 26. № 16. P. 4437–4443.

Torta D., Legrain V., Mouraux A., Valentini E. Attention to pain! A neurocognitive perspective on attentional modulation of pain in neuroimaging studies // Cortex. 2017. Vol. 89. P. 120–134.

Orme-Johnson D. W., Schneider R. H., Son Y. D., Nidich S., Cho Z. H. Neuroimaging of meditation’s effect on brain reactivity to pain // Neuroreport. 2006. August 21. Vol. 17. № 12. P. 1359–1363.

Bausell R., Lao L., Bergman S., Lee W.-L., Berman B. M. Is acupuncture analgesia an expectancy effect? Preliminary evidence based on participants’ perceived assignments in two placebo-controlled trials // Evaluation & the Health Professions. 2005. Vol. 28. P. 9–26.

Colloca L., Lopiano L., Lanotte M., Benedetti F. Overt versus covert treatment for pain, anxiety, and Parkinson’s disease // The Lancet Neurology. 2004. Vol. 3. № 11. P. 679–684.

Benedetti F., Carlino E., Pollo A. Hidden administration of drugs // Clinical Pharmacology & Therapeutics. 2011. November. Vol. 90. № 5. P. 651–661.

Levine J. D., Gordon N. C., Smith R., Fields R. L. Analgesic responses to morphine and placebo in individuals with postoperative pain // Pain. 1981. Vol. 10. № 3. P. 379–389.

Levine J. D., Gordon N. C. Influence of the method of drug administration on analgesic response // Nature. 1984. Vol. 312. P. 755–756.

Kirsch I., Lynn S. J., Vigorito M., Miller R. R. The role of cognition in classical and operant conditioning // Journal of Clinical Psychology. 2004. Vol. 60. № 4. P. 369–392.

Gracely R. H., Dubner R., Wolskee P. J., Deeter W. R. Placebo and naloxone can alter postsurgical pain by separate mechanisms // Nature. 1983. Vol. 306. P. 264–265.

Lipman J. J., Miller B. E., Mays K. S., Miller M. N., North W. C., Byrne W. L. Peak B endorphin concentration in cerebrospinal fluid: reduced in chronic pain patients and increased during the placebo response // Psychopharmacology. 1990. September. Vol. 102. № 1. P. 112–116.

Benedetti F., Amanzio M., Maggi G. Potentiation of placebo analgesia by proglumide // Lancet. 1995. Vol. 346. № 8984. P. 1231.

Benedetti F., Amanzio M., Thoen W. Disruption of opioid-induced placebo responses by activation of cholecystokinin type-2 receptors // Psychopharmacology. 2011. Vol. 213. № 4. P. 791–797.

Zubieta J. K., Bueller J. A., Jackson L. R. et al. Placebo effects mediated by endogenous opioid activity on mu-opioid receptors // Journal of Neuroscience. 2005. August 24. Vol. 25. № 34. P. 7754–7762.

Benedetti F., Amanzio M., Rosato R. et al. Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors // Nature Medicine. 2011. Vol. 17. № 10. P. 1228–1230.

Rea K., Roche M., Finn D. P. Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate // British journal of pharmacology. 2007. November. Vol. 152. № 5. P. 633–648.

Rozenzweig P., Brohier S., Zipfel A. The placebo effect in healthy volunteers: influence of experimental conditions on the adverse events profile during phase I studies // Clinical Pharmicology and Therapeutics. 1993. November 1. Vol. 54. № 5. P. 578–583.

Silvestri A., Galetta P., Cerquetani E. et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo // European Heart Journal. 2003. Vol. 24. № 21. P. 1928–1932.

Mondaini N., Gontero P., Giubilei G., Lombardi G., Cai T., Gavazzi A. et al. Finasteride 5 mg and sexual side effects: How many of these are related to a nocebo phenomenon? // Journal of Sexual Medicine. 2007. Vol. 4. № 6. P. 1708–1712.

Swider K., Bąbel P. The effect of the sex of a model on nocebo hyperalgesia induced by social observational learning // Pain. 2013. Vol. 154. № 8. P. 1312–1317.

Copeman W. S. Andrew Ure, M. D., F. R. S. (1778–1857) // Proceedings of the Royal Society of Medicine. 1951. August. Vol. 44. № 8. P. 655–662.

Oftedal G., Straume A., Johnsson A., Stovner L. J. Mobile phone headache: A double blind, sham-controlled provocation study // Cephalalgia. 2007. June. Vol. 27. № 5. P. 447–455.

Jones T. Mass psychogenic illness: Role of the individual physician // American Family Physician. 2000. Decemder 15. Vol. 62. № 12. P. 2649–2653.

Bartholomew R., Wessely S. Protean nature of mass sociogenic illness // The British Journal of Psychiatry. 2002. Vol. 180. P. 300–306.

Clements C. J. Mass psychogenic illness after vaccination // Drug Safety. 2003. Vol. 26. № 9. P. 599–604.

Kim S. Y., Frank S., Holloway R., Zimmerman C., Wilson R., Kieburtz K. Science and ethics of sham surgery: a survey of Parkinson disease clinical researchers // Archives of Neurology. 2005. September. Vol. 62. № 9. P. 1357–1360.

Sihvonen R., Paavola M., Malmivaara A., Itälä A., Joukainen A., Nurmi H. et al. Arthroscopic partial meniscectomy versus sham surgery for a degenerative meniscal tear // The New England journal of Medicine. 2013. Vol. 369. P. 2515–2524.

Van der Windt D. A., Van der Heijden G., Van den Berg S. G., Ter Riet G. Ultrasound therapy for acute ankle sprains // Cochrane Database of Systematic Reviews. 2002. 2: CD001250.

Donaldson I. (trans, ed.) The reports of the royal commision of 1784 on Mesmer’s system of animal magnetism, and other contemporary documents. Edinburgh: James Lind Library/Sibbald Library, 2014.

Darnton R. Mesmerism and the end of the Enlightenment in France. Harvard University Press, 2009.

Braid J. Magic, witchcraft, animal magnetism. London, 1852.

Braid J. The complete writings of James Braid. Lulu.com, 2013.

Kaptchuk T. J., Shaw J., Kerr C. E., Conboy L. A., Kelley J. M., Thomas J. et al. “Maybe I made up the whole thing”: placebos and patients’ experiences in a randomized controlled trial // Culture, medicine and psychiatry. 2009. September. Vol. 33. № 3. P. 382–411.

Kienle G. S., Kiene H. The powerful placebo effect: fact or fiction? // Journal of Clinical Epidemiology. 1997. Vol. 50. № 12. P. 1311–1318.

Brown-Sequard C. E. The effects produced on man by subcutaneous injections of a liquid obtained from the testicules of animals // Lancet. 1889. July 20. Vol. 2. P. 105–107.

Cussons A. J., Bhagat C. I., Fletcher S. J., Walsh J. P. Brown-Séquard revisited: a lesson from history on the placebo effect of androgen treatment // The Medical Journal of Australia. 2002. December. Vol. 177. № 11. P. 678–679.

Matfin G. The rejuvenation of testosterone: philosopher’s stone or Brown-Séquard Elixir? // Therapeutic advances in endocrinology and metabolism. 2010. August. Vol. 1. № 4. P. 151–154.

Conway A. J., Handelsman D. J., Lording D. W., Stuckey B., Zajac J. D. Use, misuse and abuse of androgens. The Endocrine Society of Australia consensus guidelines for androgen prescribing // The Medical Journal of Australia. 2000. March 6. Vol. 172. № 5. P. 220–224.

Clark W. C., Mehl L. Thermal pain: A sensory decision theory analysis of the effect of age and sex on d’ various response criteria, and 50% pain threshold // Journal of Abnormal Psychology. 1971. Vol. 78. № 2. P. 202–212.

Lewis S. C., Warlow C. P. How to spot bias and other potential problems in randomised controlled trials // Journal of Neurology, Neurosurgery & Psychiatry. Vol. 75. № 2. P. 181–187.

Hofer A., Hummer M., Huber R., Kurz M., Walch T., Fleischhacker W. W. Selection bias in clinical trials with antipsychotics // Journal of Clinical Psychopharmacology. 2000. December. Vol. 20. № 6. P. 699–702.

Hodges R. D., Scofield A. M. Is spiritual healing a valid and effective therapy? // Journal of the Royal Society of Medicine. 1995. Vol. 88. № 4. P. 203–207.

Abbot N. C., Harkness E. F., Stevinson C., Marshall F. P., Conn D. A., Ernst E. Spiritual healing as a therapy for chronic pain: a randomized, clinical trial // Pain. 2001. Vol. 91. № 1–2. P. 79–89.

Miller L. E., Stewart M. E. The blind leading the blind: Use and misuse of blinding in randomized controlled trials // Contemporary Clinical Trials. 2011. Vol. 32. № 2. P. 240–243.

Misra S. Randomized double blind placebo control studies, the “Gold Standard” in intervention based studies // Indian journal of sexually transmitted diseases and AIDS. 2012. July-December. Vol. 33. № 2. P. 131–134.

Jadad A. R., Enkin M. W. Randomized controlled trials: questions, answers, and musings. Blackwell Publishing, 2007.

George S. L. Perspectives on scientific misconduct and fraud in clinical trials // Chance. 1997. Vol. 10. № 4. P. 3–5.

Schulz K. F., Chalmers I., Hayes R. J., Altman D. G. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials // JAMA. 1995. Vol. 273. № 5. P. 408–412.

Steneck N. H. Assessing the Integrity of Publicly Funded Research. A Background Report for the ORI Research Conference on Research Integrity. 2000.

George S. L., Buyse M. Data fraud in clinical trials // Clinical investigation. 2015. Vol. 5. № 2. P. 161–173.

Woodhead M. 80% of China’s clinical trial data are fraudulent, investigation finds // BMJ. 2016. Vol. 355: i5396.

Djulbegovic B., Lacevic M., Cantor A., Fields K. K., Bennett C. L., Adams J. R. et al. The uncertainty principle and industry-sponsored research // Lancet. 2000. August 19. Vol. 356. P. 635–638.

Lexchin J., Bero L. A., Djulbegovic B., Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review // BMJ. 2003. Vol. 326. P. 1167–1170.

Davidson R. A. Source of funding and outcome of clinical trials // Journal of General Internal Medicine. 1986. May. Vol. 1. № 3. P. 155–158.

Medical Research Council. Clinical trial of patulin in the common cold // Lancet. 1944. September 16. Vol. 244. № 6316. P. 373–375.

Carneiro A. V. Bias in clinical studies // Revista portuguesa de cardiologia. 2011. February. Vol. 30. № 2. P. 235–242.

Raistrick H., Birkinshaw J. H., Michael S. E., Bracken A., Gye W. E. et al. Patulin in the common cold. Collaborative research on a derivative of Penicillium patulum Bainier // Lancet. 1943. November 20. Vol. 245. P. 625–635.

Stansfeld J. M., Francis A. E., Stuart-Harris C. H. Laboratory and clinical trials of patulin // Lancet. 1944. September 16. P. 370–372.

Clarke M. The 1944 patulin trial of the British Medical Research Council // Journal of the Royal Society of Medicine. 2006. September. Vol. 99. № 9. P. 478–480.

D’Arcy Hart P. A change in scientific approach: from alternation to randomised allocation in clinical trials in the 1940s // BMJ. 1999. August 28. Vol. 319. № 7209. P. 572–573.

Balabanova Y., Coker R., Fedorin I., Zakharova S., Plavinskij S., Krukov N. et al. Variability in interpretation of chest radiographs among Russian clinicians and implications for screening programmes: observational study // BMJ. 2005. August 13. Vol. 331. № 7513. P. 379–382.

Regev A., Berho M., Jeffers L. J., Milikowski C., Molina E. G. et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection // American Journal of Gastroenterology. 2002. Vol. 97. P. 2614–2618.

Cooperberg M. R., Chi T., Jad A., Cha I., Turek P. J. Variability in testis biopsy interpretation: implications for male infertility care in the era of intracytoplasmic sperm injection // Fertility and sterility. 2005. September. Vol. 84. № 3. P. 672–677.

Elmore J. G., Nelson H. D., Pepe M. S., Longton G. M. et al. Variability in pathologists’ iterpretations of individual breast biopsy slides: A population perspective // Annals of Internal Medicine. 2016. Vol. 164. № 10. P. 649–655.

Smith-Bindman R., Hosmer W. D., Caponigro M., Cunningham G. The variability in the interpretation of prenatal diagnostic ultrasound // Ultrasound in Obstetrics & Gynecology. 2001. April. Vol. 17. № 4. P. 326–332.

Mussurakis S., Buckley D. L., Coady A. M., Turnbull L. W., Horsman A. Observer variability in the interpretation of contrast enhanced MRI of the breast // The British journal of radiology. 1996. November. Vol. 69. № 827. P. 1009–1016.

Physical defects: The pathway to correction. New York: American Child Health Association 1934.

Ayanian J. Z., Berwick D. M. Do physicians have a bias toward action? A classic study revisited // Medical Decision Making. 1991. Vol. 11. № 3. P. 154–158.

Boylston Z. An account of the small-pox inoculated in New England, upon all sorts of persons, whites, blacks and of all ages and constitutions. The Second edition. London: Printed for S. Chandler. Reprinted in Boston in NE for S. Gerrism in Cornhil and T. Hancock, 1730.

Torgerson D. J., Roberts C. Randomisation methods: concealment // BMJ. 1999. August 7. Vol. 319. № 7206. P. 375–376.

Schulz K. F. Subverting randomization in controlled trials // JAMA. 1995. November 8. Vol. 274. № 18. P. 1456–1458.

Julious S. A., Mullee M. A. Confounding and Simpson’s paradox // BMJ. 1994. December. Vol. 309. № 6967. P. 1480–1481.

Charig C. R., Webb D. R., Payne S. R., Wickham J. E. Comparison of treatment of renal calculi by open surgery, percutaneous nephrolithotomy, and extracorporeal shockwave lithotripsy // British Medical Journal. (Clinical research ed.). 1986. March 29. Vol. 292. № 6524. P. 879–882.

Kunz R., Vist G., Oxman A. D. Randomisation to protect against selection bias in healthcare trials // The Cochrane database of systematic reviews. 2007. April. Vol. 18. № 2, MR000012.

Antman K., Amato D., Wood W., Carson J., Suit H., Proppe K. et al. Selection bias in clinical trials // Journal of Clinical Oncology. 1985. August. Vol. 3. № 8. P. 1142–1147.

Vickers A. J. How to randomize // Journal of the Society for Integrative Oncology. 2006. Vol. 4. № 4. P. 194–198.

Suresh K. P. An overview of randomization techniques: An unbiased assessment of outcome in clinical research // Journal of human reproductive sciences. 2011. January-April. Vol. 4. № 1. P. 8–11.

Beller E. M., Gebski V., Keech A. C. Randomisation in clinical trials // Medical Journal of Australia. 2002. Vol. 177. № 10. P. 565–567.

Porter T. M. The Rise of Statistical Thinking, 1820–1900. Princeton University Press, 1986.

Fisher R. A. The arrangement of field experiments // Journal of the Ministry of Agriculture of Great Britain. 1926. Vol. 33. P. 503–513.

Nolan D., Speed T. Stat Labs: Mathematical statistics through applications. Springer-Verlag, New York, 2000.

Fisher R. A. Mathematics of a lady tasting tea / J. R. Newman (ed.), The world of mathematics (Third Ed., 1512–1521). New York: Simon and Schuster, 1956. P. 1512–1521.

Finney D. J. Sir Ronald Fisher’s Contributions to Biometric Statistics // Biometrics. 1964. Vol. 20. № 2. P. 322–329.

Fisher R. A. The design of experiments. Edinburgh: Oliver and Boyd, 1960.

Hróbjartsson A., Gøtzsche P. C., Gluud C. The controlled clinical trial turns 100 years: fibiger’s trial of serum treatment of diphtheria // BMJ. 1998. Vol. 317. № 7167. P. 1243–1245.

Hall N. S. R. A. Fisher and his advocacy of randomization // Journal of the history of biology. 2007. Summer. Vol. 40. № 2. P. 295–325.

Kennedy A., Torgerson D. J., Campbell M. K., Grant A. M. Subversion of allocation concealment in a randomised controlled trial: a historical case study // Trials. 2017. Vol. 18. P. 204.

Schulz K. F., Chalmers I., Grimes D. A., Altman D. G. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals // JAMA. 1994. Vol. 272. № 2. P. 125–128.

Kahan B. C., Morris T. P. Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysis // BMJ. 2012. Vol. 345: e5840.

Ah-See K. W., Molony N. C. A qualitative assessment of randomized controlled trials in otolaryngology // The Journal of Laryngology & Otology. 1998. Vol. 112. № 5. P. 460–463.

Britton A., McKee M., Black N., McPherson K., Sanderson C. et al. Choosing between randomised and non-randomised studies: a systematic review // Health Technology Assessment. 1998. October. Vol. 2. № 13.

Galton F. Statistical inquiries into the efficacy of prayer // Fortnightly Review. 1872. Vol. 12. P. 125–135.

Stigler S. M. Francis Galton’s account of the invention of correlation // Statistical Science. 1989. Vol. 4. № 2. P. 73–79.

Statistics at Square One (ninth edition, revised by M. J. Campbell, T. D. V. Swinscow). BMJ Publ. Group, London, 1996.

Stanton J. M. Galton, Pearson, and the peas: A brief history of linear regression for statistics instructors // Journal of Statistics Education. 2001. Vol. 9. № 3.

Lyon A. Why are Normal Distributions Normal? // British Journal for the Philosophy of Science. 2014. Vol. 65. № 3. P. 621–649.

Forbes E. G. Gausse and the discovery of ceres // JHA. 1971. Vol. 2. P. 195–199.

Sheynin O. B. Laplace’s theory of errors // Archive for History of Exact Sciences. 1977. May. Vol. 17. № 1. P. 1–61.


Часть третья

Franco N. H. Animal experiments in biomedical research: A historical perspective // Animals. 2013. Vol. 3. № 1. P. 238–273.

Guerrini A. Experimenting with humans and animals. From Galen to animal rights. Johns Hopkins University Press, 2003.

Perel P., Roberts I., Sena E., Wheble P., Briscoe C., Sandercock P., Macleod M. et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review // BMJ. 2007. January 27. Vol. 334. № 7586. P. 197–200.

An account of the experiment of transfusion, practised upon a man in London // Philosophical Transactions. 1667. Vol. 30. № 2. P. 557–559.

Dorrington K. L., Poole W. The first intravenous anaesthetic: how well was it managed and its potential realized? // British Journal of Anaesthesia. 2013. January. Vol. 110. № 1. P. 7–12.

Lamba N., Holsgrove D., Broekman M. L. The history of head transplantation: a review // Acta Neurochirurgica. 2016. Vol. 158. № 12. P. 2239–2247.

The ethics of research involving animals. London: Nuffield Council on Bioethics, 2005.

Maehle A.-H., Tröhler U. Animal experimentation from antiquity to the end of the eighteenth century: Attitudes and arguments / Rupke N. A. (ed.) Vivisection in Historical Perspective. London: Croom Helm, 1987.

Prejean J. D., Peckham J. C., Casey A. E., Griswold D. P., Weisburger E. K., Weisburger J. H. Spontaneous Tumors in Sprague-Dawley Rats and Swiss Mice // Cancer research. 1973. November. Vol. 33. № 11. P. 2768–2773.

Liddick D. R. Eco-terrorism: radical environmental and animal liberation movements. New York: Praeger, 2006.

Scutti S. Animal testing: A long, unpretty history // Medical Daily. 2013. June 27.

Ormandy E. H., Schuppli C. A., Weary D. M. Worldwide trends in the use of animals in research: The contribution of genetically-modified animal models // Alternatives to laboratory animals. 2009. Vol. 37. № 1. P. 63–68.

Weisse A. B. Self-experimentation and its role in medical research // Texas Heart Institute journal. 2012. Vol. 39. № 1. P. 51–54.

Altman L. K. Who goes first?: The story of self-experimentation in medicine. University of California Press, 1998.

Gladstein J. Hunter’s chancre: did the surgeon give himself syphilis? // Clinical Infectious Diseases. 2005. Vol. 41. P. 128–129.

Reed W., Carroll J., Agramonte A., Lazear J. W. The etiology of yellow fever – a preliminary note // Public Health Papers and Reports. 1900. Vol. 26. P. 37–53.

Marshall B. J., Warren R. Unidentified curved bacilli on gastric epithelium in active chronic gastritis // Lancet. 1984. June 16. Vol. 323. № 8390. P. 1311–1315.

Hellström P. M. This year’s Nobel Prize to gastroenterology: Robin Warren and Barry Marshall awarded for their discovery of Helicobacter pylori as pathogen in the gastrointestinal tract // World journal of gastroenterology. 2006. May 21. Vol. 12. № 19. P. 3126.

Blackadar C. B. Historical review of the causes of cancer // World journal of clinical oncology. 2016. February 10. Vol. 7. № 1. P. 54–86.

Stubbins F. A treatise on malignant fever: with an attempt to prove its noncontagious nature. Philadelphia, 1804.

Buzzi A. Claude Bernard on cardiac catheterization // The American Journal of Cardiology. 1959. September. Vol. 4. № 3. P. 405–409.

Heiss H. W. Werner Forssmann: a German problem with the Nobel Prize // Clinical Cardiology. 1992. Vol. 15. № 7. P. 547–549.

Boring E. G. The sensations of the alimentary canal // The American Journal of Psychology. 1915. January. Vol. 26. № 1. P. 1–57.

Tarasova L. P. Experiments by I. I. Mechnikov on the study of cholera // Zhurnal mikrobiologii, epidemiologii, i immunobiologii. 1965. February. Vol. 42. P. 145–149.

Lakhtakia R., Burney I. Self-experimenting physicians: Mavericks or martyrs? // Sultan Qaboos University Medical Journal. 2015. November. Vol. 15. № 4, e452–455.

Long C. W. An account of the first use of sulphuric ether by inhalation as an anaesthetic in surgical operations // Survey of Anesthesiology. 1991. December. Vol. 35. № 6. P. 375.

Klockgether-Radke A. P. F. W. Sertürner and the discovery of morphine. 200 years of pain therapy with opioids // Anasthesiol Intensivmed Notfallmed Schmerzther. 2002. May. Vol. 37. № 5. P. 244–249.

Benzenhöfer U., Passie T. Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin // Addiction. Vol. 105. P. 1355–1361.

Zuardi A. W. History of cannabis as a medicine: a review // Brazilian Journal of Psychiatry. 2006. June. Vol. 28. № 2. P. 153–157.

Holmstedt B., Liljestrand G. (eds.) Readings in Pharmacology. New York: The Macmillan Company, 1963.

Swan M. Health 2050: The realization of personalized medicine through crowdsourcing, the quantified self, and the participatory biocitizen // Journal of Personalized Medicine. 2012. Vol. 2. № 3. P. 93–118.

Bode M., Kristensen D. B. The digital doppelgänger within. A study on self-tracking and the quantified self-movement / Canniford R., Bajde D. (eds.) Assembling consumption: researching actors, networks and markets. New York: Routledge, 2016. P. 119–134.

Lee V. R. What’s Happening in the “Quantified Self” Movement? Instructional Technology and Learning Sciences Faculty Publications. 2014. P. 1032–1036.

Bjelakovic G., Nikolova D., Gluud L. L., Simonetti R. G., Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases // Cochrane Database of Systematic Reviews. 2008. № 3. Art. № CD007176.

Bókkon I. Recognition of functional roles of free radicals // Current neuropharmacology. 2012. December. Vol. 10. № 4. P. 287–288.

Knight J. A. Review: Free radicals, antioxidants, and the immune system // Annals o f Clinical & Laboratory Science. 2000. Vol. 30. № 2. P. 145–158.

Dröge W. Free radicals in the physiological control of cell function // Physiological reviews. 2002. Vol. 82. P. 47–95.

Ossola A. These biohackers are creating open-source insulin // Popular Science. 2015. November 19.

Srader D. W. The Nuremberg doctors’ trial: framing collective memory through argument. The University of Georgia. 2003.

Hornblum A. M. They were cheap and available: prisoners as research subjects in twentieth century America // BMJ. 1997. November 29. Vol. 315. P. 1437–1441.

Rice, J. B. (reported) Interrogation of General Gerhard Rose: vice-president of the Robat Koch Institute, Berlin, chief consultant in tropical medicine to the German Air Force. [England?]: Combined Intelligence Objectives Sub-Committee, [not before June 1945].

Chernin E. Richard Pearson Strong and the Iatrogenic Plague Disaster in Bilibid Prison, Manila, 1906 // Reviews of Infectious Diseases. 1989. November-December. Vol. 11. № 6. P. 996–1004.

The Lübeck catastrophe // British Medical Journal. 1931. June 6. Vol. 1. P. 986.

Vollmann J., Winau R. Nuremberg doctors’ trial: informed consent in human experimentation before the Nuremberg code // BMJ. 1996. December 7. Vol. 313. № 7070. P. 1445–1447.

Langer E. Human experimentation: Cancer studies at Sloan-Kettering stir public debate on medical ethics // Science. 1964. February 7. Vol. 143. № 3606. P. 551–553.

Thomas S. B., Quinn S. C. The Tuskegee Syphilis Study, 1932 to 1972: implications for HIV education and AIDS risk education programs in the black community // American Journal of Public Health. 1991. November. Vol. 81. № 11. P. 1498–1505.

Brandt A. M. Racism and research: The case of the Tuskegee Syphilis study // The Hastings Center Report. 1978. Vol. 8. № 6. P. 21–29.

Corbie-Smith G. The continuing legacy of the Tuskegee Syphilis Study: Considerations for clinical investigation // The American Journal of the Medical Sciences. 1999. January. Vol. 317. № 1. P. 5–8.

Reverby S. M. More than fact and fiction: Cultural memory and the Tuskegee syphilis study // The Hastings Center Report. 2001. September-October. Vol. 31. № 5. P. 22–28.

Annas G. J. The changing landscape of human experimentation: Nuremberg, Helsinki and Beyond // Health Matrix: The Journal of Law-Medicine. 1992. Vol. 2. № 2. P. 119–140.

Seidelman W. E. Nuremberg lamentation: for the forgotten victims ofmedical science // BMJ. 1996. December 7. Vol. 313. № 7070. P. 1463–1467.

Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law No. 10. Washington, D. C.: U. S. Government Printing Office, 1949. Vol. 2. P. 181–182.

Public health // JAMA. 1896. June 6. Vol. XXVI. № 23. P. 1138–1140.

Report IV. Contemporary Issues in Medicine: Basic Science and Clinical Research. Medical School Objectives Project, 2001.

Millum J., Grady C. The ethics of placebo-controlled trials: methodological justifications // Contemporary clinical trials. 2013. November. Vol. 36. № 2. P. 510–514.

Challenging ethical issues in contemporary research on human beings. National Health and Medical Research Council (NHMRC). Canberra, ACT: Australian Government, 2007.

Hiltner S. The Tuskegee Syphilis Study under review // Christian century. 1973. November 28. Vol. 90. № 43. P. 1174–1176.

Howard-Jones N. Human experimentation in historical and ethical perspectives // Social Science & Medicine. 1982. Vol. 16. № 15. P. 1429–1448.

Bernstein J. E. Ethical considerations in human experimentation // Journal of clinical pharmacology. 1975. August- September. Vol. 15. № 8–9. P. 579–590.

Katz R. V. The legacy of the Tuskegee Syphilis Study: assessing its impact on willingness to participate in biomedical studies // Journal of health care for the poor and underserved. 2008. November. Vol. 19. № 4. P. 1168–1180.

Rasko J., Power C. Dr Con Man: the rise and fall of a celebrity scientist who fooled almost everyone // The Guardian. 2017. September 1.

The Macchiarini case: investigation of the synthetic trachea transplantations at Karolinska University Hospital. 2016. August 31.

Novella S. Selling Stem Cell Hype // Skeptical Inquirer. 2011. September/October. Vol. 35.5.

Shuster E. Fifty years later: The significance of the Nuremberg Code // The New England Journal of Medicine. 1997. November. Vol. 337. P. 1436–1440.

The Human Radiation Experiments: Final Report of the Advisory Committee on Human Radiation Experiments. Oxford University Press, 1996.

Киселев В. А. Биоэтический словарь. 2-е изд., испр. и доп. Екатеринбург: УГМА, 2006


Часть четвертая

Vineis P. History of bias // Sozial-und Präventivmedizin. 2002. September. Vol. 47. № 3. P. 156–161.

Buck C., Llopis A. et al. The challenge of epidemiology: issues and selected readings. Pan American Health Org, 1988.

Karamanou M., Panayiotakopoulos G., Tsoucalas G., Kousoulis A., Androutsos G. From miasmas to germs: a historical approach to theories of infectious disease transmission // Le Infezioni in Medicina. 2012. March. Vol. 20. № 1. P. 58–62.

Sterner C. S. Brief history of miasmic theory // Bulletin of the History of Medicine. 1948. Vol. 22.

Юркова З. В. Сенная площадь. Вчера, сегодня, завтра. М.: Центрполиграф, 2011.

Bosin Y. V. Russia, cholera riots of 1830–1831 / Ness I. ed. International Encyclopedia of Revolution and Protest. Blackwell Publishing, 2009. P. 2877–2878.

McGrew R. E. The first Russian cholera epidemic: themes and opportunities // Bulletin of the History of Medicine. 1962. January 1. Vol. 36. P. 220.

Snow J. The cholera at Albion terrace // London Medical Gazette. 1849. September. Vol. 44. P. 504–505.

Hill A. B. Snow – An Appreciation // Proceedings of the Royal Society of Medicine. 1955. Vol. 48. P. 1008–1012.

Parkes E. A. Mode of Communication of Cholera. By John Snow, MD: Second Edition – London, 1855, pp 162 // International Journal of Epidemiology. 2013. Vol. 42. № 6. P. 1543–1552.

Snow J. On the mode of communication of cholera. John Churchill, 1855.

Budd W. Malignant Cholera: its cause, mode of propagation, and prevention // International Journal of Epidemiology. 2013. Vol. 42. № 6. P. 1567–1575.

Smith G. D. Commentary: Behind the Broad Street pump: aetiology, epidemiology and prevention of cholera in mid-19th century Britain // International Journal of Epidemiology. 2002. October. Vol. 31. № 5. P. 920–932.

Ackerknecht E. H. Anticontagionism between 1821 and 1867: The Fielding H. Garrison Lecture // International Journal of Epidemiology. 2009. February. Vol. 38. № 1. P. 7–21.

Koch R. An address on cholera and its bacillus // British Medical Journal. 1884. September. Vol. 2. № 1236. P. 453–459.

Howard-Jones N. Robert Koch and the cholera vibrio: a centenary // British medical journal (Clinical research ed.). 1984. February 4. Vol. 288. № 6414. P. 379–381.

Blevins S. M., Bronze M. S. Robert Koch and the ‘golden age’ of bacteriology // International Journal of Infectious Diseases. 2010. September. Vol. 14. № 9, e744–751.

Barua D. The global epidemiology of cholera in recent years // Proceedings of the Royal Society of Medicine. 1972. May. Vol. 65. № 5. P. 423–428.

Cholera vaccines: WHO position paper // Weekly Epidemiological Record. 2010. Vol. 85. № 13. P.117–128.

Rothman K. J., Greenland S. Types of Epidemiologic Studies / Rothman K. J., Greenland S. Modern Epidemiology. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 1998. P. 67–78.

Vandenbroucke J. P., Pearce N. Case – control studies: basic concepts // International Journal of Epidemiology. 2012. Vol. 41. № 5. P. 1480–1489.

Rubin D. B. Estimating causal effects of treatments in randomized and nonrandomized studies // Journal of Educational Psychology. 1974. Vol. 66. № 5. P. 688–701.

Parascandola M. Two approaches to etiology: the debate over smoking and lung cancer in the 1950s // Endeavour. 2004. June. Vol. 28. № 2. P. 81–86.

White C. Research on smoking and lung cancer: A landmark in the history of chronic disease epidemiology // The Yale Journal of Biology and Medicine. 1990. Vol. 63. № 1. P. 29–46.

Mahmood S. S., Levy D., Vasan R. S., Wang T. J. The framingham heart study and the epidemiology of cardiovascular diseases: A historical perspective // Lancet. 2014. March 15. Vol. 383. № 9921. P. 999–1008.

Song J. W., Chung K. C. Observational studies: Cohort and case-control studies // Plastic and reconstructive surgery. 2010. December. Vol. 126. № 6. P. 2234–2242.

Ending the tobacco problem: A blueprint for the nation. Washington, DC: Institute of Medicine, 2007.

Ridge C. A., McErlean A. M., Ginsberg M. S. Epidemiology of Lung Cancer // Seminars in interventional radiology. 2013. June. Vol. 30. № 2. P. 93–98.

Talhout R., Schulz T., Florek E., Van Benthem J., Wester P., Opperhuizen A. Hazardous compounds in tobacco smoke // International journal of environmental research and public health. 2011. February. Vol. 8. № 2. P. 613–628.

Pfeifer G. P, Denissenko M. F., Olivier M., Tretyakova N., Hecht S. S., Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers // Oncogene. 2002. October. Vol. 21. P. 7435–7451.

Hecht S. S. Tobacco smoke carcinogens and lung cancer // Journal of the National Cancer Institute. 1999. July 21. Vol. 91. № 14. P. 1194–1210.

Hecht S. S. Carcinogenicity studies of inhaled cigarette smoke in laboratory animals: old and new // Carcinogenesis. 2005. Vol. 26. № 9. P. 1488–1492.

Tobacco smoke and involuntary smoking / IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 83. International Agency for Research on Cancer, Lyon, 2004.

Glantz S. A., Bero L. A., Slade J., Barnes D. E., Hanauer P. (eds.). The Cigarette Papers. University of California Press, 1998.

Fisher R. Cigarettes, cancer, and statistics // The Centennial Review of Arts & Science. 1958. Vol. 2. P. 151–166.

Heath C. W. Differences between smokers and nonsmokers // Archives of Internal Medicine. 1958. February. Vol. 101. № 2. P. 377–388.

Morris J. N., Crawford M. D. Coronary heart disease and physical activity of work: Evidence of a national necropsy survey // British Medical Journal. 1958. December 20. Vol. 2. № 5111. P. 1485–1496.

Morris J. N., Clayton D. G., Everitt M. G., Semmence A. M., Burgess E. H. Exercise in leisure time: coronary attack and death rates // British heart journal. 1990. Vol. 63. № 3. P. 325–334.

Fedak K. M., Bernal,A., Capshaw Z. A., Gross S. Applying the Bradford Hill criteria in the 21st century: how data integration has changed causal inference in molecular epidemiology // Emerging themes in epidemiology. 2015. Vol. 12. № 1. P. 14.

Howick J., Glasziou P., Aronson J. K. The evolution of evidence hierarchies: what can Bradford Hill’s ‘guidelines for causation’ contribute? // Journal of the Royal Society of Medicine. 2009. Vol. 102. № 5. P. 186–194.

Di Cicco M. E., Ragazzo V., Jacinto T. Mortality in relation to smoking: the British Doctors Study // Breathe (Sheffield, England). 2016. September. Vol. 12. № 3. P. 275–276.

Dearlove J. V., Bialous S. A., Glantz S. A. Tobacco industry manipulation of the hospitality industry to maintain smoking in public places // Tobacco Control. 2002. Vol. 11. № 2. P. 94–104.

Smith C. N., Kraemer J. D., Johnson A. C., Mays D. Plain packaging of cigarettes: do we have sufficient evidence? // Risk management and healthcare policy. 2015. Vol. 8. P. 21–30.

Ong E. K., Glantz S. A. Constructing “sound science” and “good epidemiology”: Tobacco, lawyers, and public relations firms // American journal of public health. 2001. November. Vol. 91. № 11. P. 1749–1757.

Bero L. A. Tobacco industry manipulation of research // Public Health Reports. 2005. March/April. Vol. 120. № 2. P. 200–208.

Velicer C., Helen G., Glantz S. A. Tobacco papers and tobacco industry ties in regulatory toxicology and pharmacology // Journal of public health policy. 2018. February. Vol. 39. № 1. P. 34–48.

Boffetta P., Couto E., Wichmann J., Ferrari P., Trichopoulos D. et al. Fruit and vegetable intake and overall cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) // Journal of the National Cancer Institute. 2010. April 21. Vol. 102. № 8. P. 529–537.

Siontis G. C. M., Ioannidis J. P. A. Risk factors and interventions with statistically significant tiny effects // International Journal of Epidemiology. 2011. October. Vol. 40. № 5. P. 1292–1307.

De Boer M., Van Leeuwen F. E., Hauptmann M., Overbeek L. et al Breast implants and the risk of anaplastic large-cell lymphoma in the breast // JAMA Oncology. 2018. Vol. 4. № 3. P. 335–341.

Doren E. L., Miranda R. N., Selber J. C., Garvey P. B., Liu J., Medeiros L. J. et al. U. S. epidemiology of breast implant-associated anaplastic large cell lymphoma // Plastic and reconstructive surgery. 2017. May. Vol. 139. № 5. P. 1042–1050.

Bouvard V., Loomis D., Guyton K. Z., Grosse Y., Ghissassi F. et al. Carcinogenicity of consumption of red and processed meat // Lancet Oncology. 2015. December. Vol. 16. P. 1599–1600.

Food, nutrition, physical activity, and the prevention of cancer: a global perspective. World Cancer Research Fund / American Institute for Cancer Research. Washington DC: AICR, 2007.

Chan D. S., Lau R., Aune D., Vieira R., Greenwood D. C., Kampman E., Norat T. Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies // PLoS One. 2011. Vol. 6. № 6, e20456.

Truswell A. S. Problems with red meat in the WCRF2 // American Journal of Clinical Nutrition. 2009. Vol. 89. № 4. P. 1274–1275.

Wei E. K., Giovannucci E., Wu K., Rosner B., Fuchs C. S., Willett W. C., Colditz G. A. Comparison of risk factors for colon and rectal cancer // International Journal of Cance. 2004. January 20. Vol. 108. № 3. P. 433–442.

Tai V., Grey A., Bolland M. J. Results of observational studies: analysis of findings from the Nurses’ Health Study // PLoS One. 2014. Vol. 9. № 10, e110403.


Часть пятая

Overington J. P., Al-Lazikani B., Hopkins A. L. How many drug targets are there? // Nature reviews. Drug discovery. 2006. December. Vol. 5. № 12. P. 993–996.

Kaplan R. M., Irvin V. L. Likelihood of null effects of large NHLBI clinical trials has increased over time // Plos Оne. 2015. August 5. Vol. 10. № 8, e0132382.

Chalmers I., Glasziou P. Avoidable waste in the production and reporting of research evidence // Lancet. 2009. Vol. 374. № 9683. P. 86–89.

Prinz F., Schlange T., Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? // Nature Reviews Drug Discovery. 2011. Vol. 10. № 9. P. 712–713.

Begley C. G. Six red flags for suspect work // Nature. 2013. May 23. Vol. 497. № 7450. P. 433–434.

Begley C. G., Ellis L. M. Raise standards for preclinical cancer research // Nature. 2012. March 29. Vol. 483. P. 531–533.

Plourde G. Validation of surrogate endpoints for clinical trials // Journal of Pharmacology & Clinical Research. 2018. Vol. 5. № 2, 555657.

Васильев А. Н., Ниязов Р. Р., Гавришина Е. В., Драницына М. А., Куличев Д. А. Проблемы планирования и проведения доклинических исследований в Российской Федерации // Ремедиум. 2017. № 9. C. 6–18.

Ganellin R., Roberts S. M., Jefferies R. (eds.) Introduction to biological and small molecule drug research and development, theory and case studies. New York: Academic Press, 2013.

Patnaik A., Kang S. P., Rasco D., Papadopoulos K. P., Elassaiss-Schaap J. et al. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients With Advanced Solid Tumors // Clinical Cancer Research. 2015. Vol. 21. № 19. P. 4286–4293.

Wong C. H., Siah K. W., Lo A. W. Estimation of clinical trial success rates and related parameters // Biostatistics. 2018. January.

Lounnas V., Ritschel T., Kelder J., McGuire R., Bywater R. P., Foloppe N. Current progress in Structure-Based Rational Drug Design marks a new mindset in drug discovery // Computational and structural biotechnology journal. 2013. Vol. 5. № 6, e201302011.

Thomas D. W., Burns J., Audette J., Carroll A., Dow-Hygelund C., Hay M. Clinical development success rates 2006–2015. Biotechnology Innovation Organization. 2016. June. P. 8.

Paul S. M., Mytelka D. S., Dunwiddie C. T., Persinger C. C., Munos B. H. et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge // Nature Reviews Drug Discovery. 2010. March. Vol. 9. № 3. P. 203–214.

Schuhmacher A., Gassmann O., Hinder M. Changing R&D models in research-based pharmaceutical companies // Journal of translational medicine. 2016. Vol. 14. № 1. P. 105.

Arrowsmith J., Miller P. Trial watch: phase II and phase III attrition rates 2011–2012 // Nature reviews Drug discovery. 2013. August. Vol. 12. № 8. P. 569.

Chrisafis A. French drug trial leaves one brain dead and five critically ill // The Guardian. 2016. January 15.

Symons X. Catastrophic result in clinical trial in France // BioEdge. 2016. January17.

Allen F. ‘Like a horror film’. What was the ‘Elephant Man’ drug testing trial, what is TGN1412 and what happened to the men involved? // The Sun. 2017. February.

Attarwala H. TGN1412: From discovery to disaster // Journal of young pharmacists. 2010. July-September. Vol. 2. № 3. P. 332–336.

Tyrsin D., Chuvpilo S., Matskevich A., Nemenov D., Römer P. S., Tabares P., Hünig T. From TGN1412 to TAB08: the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis // Clinical and experimental rheumatology. 2016. July/August. Vol. 34. № 4 (Suppl 98). P. 45–48.

Hünig T. The rise and fall of the CD28 superagonis t TGN1412 and its return as TAB08: a personal account // The FEBS Journal. 2016. Vol. 283. P. 3325–3334.

Frankos V. H. FDA perspectives on the use of teratology data for human risk assessment // Fundamental and Applied Toxicology. 1985. August. Vol. 5. № 4. P. 615–625.

Schardein J. L. Chemically induced birth defects. New York: Marcel Dekker Inc, 1993.

Lumley C., Walker S. (eds.). Animal toxicity studies: their relevance for man. London: Quay, 1990. P. 49–56.

Matthews R. A. J. Medical progress depends on animal models – doesn’t it? // Journal of the Royal Society of Medicine. 2008. February. Vol. 101. № 2. P. 95–98.

Jones C. A., Watson D. J. G., Fone K. C. F. Animal models of schizophrenia // British journal of pharmacology. 2011. October. Vol. 164. № 4. P. 1162–1194.

Stebbings R., Findlay L., Edwards C., Eastwood D., Bird C., North D., Mistry Y.et al. “Cytokine storm” in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics // The Journal of Immunology. 2007. Vol. 179. № 5. P. 3325–3331.

Suntharalingam G., Perry M. R., Ward S., Brett S. J., Castello-Cortes A. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 // The New England Journal of Medicine. 2006. Vol. 355. № 10. P. 1018–1028.

Greek R., Shanks N., Rice M. J. The history and implications of testing thalidomide on animals // The Journal of Philosophy, Science & Law. 2011. October. Vol. 11. № 3. P. 1–32.

Brent R. L. Drug testing in animals for teratogenic effects: Thalidomide in the pregnant rat // The Journal of Pediatrics. 1964. May. Vol. 64. № 5. P. 762–770.

BaileyJ., Knight A., Balcombe J. The future of teratology research is in vitro // Biogenic Amines. 2005. Vol. 19. № 2. P. 97–145.

Nelson-Rees W. A., Daniels D. W., Flandermeyer R. R. Cross-contamination of cells in culture // Science. 1981. April 24. Vol. 212. № 4493. P. 446–452.

Nelson-Rees W. A., Flandermeyer R. R. Inter- and intraspecies contamination of human breast tumor cell lines HBC and BrCa5 and other cell cultures // Science. 1977. March 25. Vol. 195. № 4284. P. 1343–1344.

Lucey B. P., Nelson-Rees W. A., Hutchins G. M. Henrietta Lacks, HeLa cells, and cell culture contamination // The Archives of Pathology & Laboratory Medicine. 2009. Vol. 133. № 9. P. 1463–1467.

Neimark J. Line of attack. Christopher Korch is adding up the costs of contaminated cell lines // Science. 2015. February 27. Vol. 347. № 6225. P. 938–940.

Travis K. For phase I studies, ethical and practical concerns abound // Journal of the National Cancer Institute. 2004. September 15. Vol. 96. № 18. P. 1354–1355.

Romm C. The life of a professional guinea pig // The Atlantic. 2015. September 23.

Lemmens T., Elliott C. Justice for the Professional Guinea Pig // The American Journal of Bioethics. 2001. Vol. 1. № 2. P. 51–53.

Philippidis A. Unlucky 13: top clinical trial failures of 2017 // GEN. 2018. January 3.

Boolell M., Allen M. J., Ballard S. A., Gepi-Attee S., Muirhead G. J. et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction // International Journal of Impotence Research. 1996. June 1. Vol. 8. № 2. P. 47–52.

Couzin-Frankel J. Hope in a mouse // Science. 2014. October 03. Vol. 346. № 6205. P. 28–29.

Benjamin D. J., Berger J. O., Johnson V. E. Redefine statistical significance // Nature Human Behaviour. 2018. Vol. 2. № 1. P. 6–10.

Ioannidis J. P. A. Why most published research findings are false // PLoS Medicine. 2005. August 30. Vol. 2. № 8, e124.

Lakens D., Adolfi F. G., Albers C. J., Anvari F., Apps M. A. et al. Justify Your Alpha // Nature Human Behaviour. 2018. March 1. Vol. 2. № 3. P. 168–171.

Рубанович А. В. Пересмотр критического уровня значимости (0.005 вместо 0.05): байесовский след // Радиационная биология. Радиоэкология. 2018. Т. 58. № 5. C. 453–463.

Head M. L., Holman L., Lanfear R., Kahn A. T., Jennions M. D. The extent and consequences of p-hacking in science // PLoS Biology. 2015. Vol. 13. № 3, e1002106.

Jager L. R., Leek J. T. An estimate of the science-wise false discovery rate and application to the top medical literature // Biostatistics. 2014. January 1. Vol. 15. № 1. P. 1–12.

Геппе Н. А., Фарбер И. М., Озерская И. В., Малявина У. С., Малышев В. С., Бухаров Д. Г. Использование препарата Коризалия у детей с острым инфекционным и персистирующим аллергическим ринитом // Доктор. Ру. 2017. № 4 (133). С. 54–60.

Petrov A., Perekhvatova N., Skulachev M., Stein L., Ousler G. SkQ1 ophthalmic solution for dry eye treatment: results of a phase 2 safety and efficacy clinical study in the environment and during challenge in the controlled adverse environment model // Advances in therapy. 2016. Vol. 33. № 1. P. 96–115.

Clinical trials often unregistered, unpublished // JAMA. 2017. September 11.

Chopra S. S. Industry funding of clinical trials: benefit or bias? // JAMA. 2003. Vol. 290. № 1. P. 113–114.

Als-Nielsen B., Chen W., Gluud C., Kjaergard L. L. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? // JAMA. 2003. August 20. Vol. 290. № 7. P. 921–928.

Lundh A., Lexchin J., Mintzes B., Schroll J. B., Bero L. Industry sponsorship and research outcome // Cochrane Systematic Review – Methodology. 2017. February 16.

Ioannidis J. P. A. Why most clinical research is not useful // PLoS Medicine. 2016. June 21. Vol. 13. № 6, e1002049.

Macleod M. R., Michie S., Roberts I., Dirnagl U., Chalmers I., Ioannidis J. P A. et al. Biomedical research: increasing value, reducing waste // Lancet. 2014. January 11. Vol. 383. № 9912. P. 101–104.

Ioannidis J. P. A., Greenland S., Hlatky M. A., Khoury M. J, Macleod M. R. et al. Increasing value and reducing waste in research design, conduct, and analysis // Lancet. 2014. January 11. Vol. 383. № 9912. P. 166–175.

Ioannidis J. P. A. Perfect study, poor evidence: interpretation of biases preceding study design // Seminars in hematology. 2008. July. Vol. 45. P. 160–166.

Jefferson T., Doshi P. Multisystem failure: the story of anti-influenza drugs // BMJ. 2014. April. Vol. 348, g2263.

Abramson J. D., Rosenberg H. G., Jewell N., Wright J. M. Should people at low risk of cardiovascular disease take a statin? // BMJ. 2013. Vol. 347, f6123.

Ioannidis J. P. A. Contradicted and initially stronger effects in highly cited clinical research // JAMA. 2005. July. Vol. 294. № 2. P. 218–228.

Djulbegovic B., Loughran T. P., Hornung C. A., Kloecker G., Efthimiadis E. N. et al. The quality of medical evidence in hematology-oncology // The American journal of medicine. 1999. February. Vol. 106. P. 198–205.

Isaakidis P., Swingler G. H., Pienaar E., Volmink J., Ioannidis J. P. Relation between burden of disease and randomised evidence in sub-Saharan Africa: survey of research // BMJ. 2002. March. Vol. 324. P. 702.

Swingler G. H., Pillay V., Pienaar E. D., Ioannidis J. P. International collaboration, funding and association with burden of disease in randomized controlled trials in Africa // Bulletin of the World Health Organization. 2005. July. Vol. 83. P. 511–517.

Goldberg N. H., Schneeweiss S., Kowal M. K., Gagne J. J. Availability of Comparative Efficacy Data at the Time of Drug Approval in the United States // JAMA. 2011. May. Vol. 305. № 17. P. 1786–1789.

Van Luijn J. C., Van Loenen A. C., Gribnau F. W., Leufkens H. G. Choice of comparator in active control trials of new drugs // Annals of Pharmacotherapy. 2008. November. Vol. 42. № 11. P. 1605–1612.

Safer. D. J. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials // The Journal of nervous and mental disease. 2002. September. Vol. 190. №. 9. P. 583–592.

Lapierre Y. D., Nair N. P., Chouinard G., Awad A. G., Saxena B., Jones B. et al. A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia – a Canadian multicentre trial // Acta psychiatrica Scandinavica. 1990. April. Vol. 82. P. 72–77.

Patris M., Agussol P., Alby J. M., Brion S., Burnat G., Castelnau D. et al. A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol // Acta psychiatrica Scandinavica. 1990. April. Vol. 82. P. 78–82.

Ioannidis J. P. A. More than a billion people taking statins? Potential implications of the new cardiovascular guidelines // JAMA. 2014. February 5. Vol. 311. № 5. Р. 463–464.

Pandor A., Ara R. M., Tumur I., Wilkinson A. J., Paisley S., Duenas A. et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials // Journal of internal medicine. 2009. May. Vol. 265. № 5. P. 568–580.

Doggrell S. A. The ezetimibe controversy – can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together? // Expert opinion on pharmacotherapy. 2012. July. Vol. 13. № 10. P. 1469–1480.

Brown B. G., Taylor A. J. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? // The New England journal of Medicine. 2008. April 3. Vol. 358. P. 1504–1507.

Naci H., Ioannidis J. P. A. How good is “evidence” from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs? // Annual review of pharmacology and toxicology. 2015. Vol. 55. P. 169–189.

Cohen D. Rosiglitazone: what went wrong? // BMJ. 2010. September. Vol. 341, c4848.

Harris G. Diabetes drug maker hid test data, files indicate // The New York Times. 2010. July 3.

Fleming T. R., Powers J. H. Biomarkers and surrogate endpoints in clinical trials // Statistics in medicine. 2012. November 10. Vol. 31. № 25. P. 2973–2984.

Svensson S., Menkes D. B., Lexchin J. Surrogate outcomes in clinical trials: a cautionary tale // JAMA. 2013. Vol. 173. № 8. P. 611–612.

Fleming T. R., DeMets D. L. Surrogate end points in clinical trials: are we being misled? // Annals of Internal Medicine. 1996. October 1. Vol. 125. № 7. P. 605–613.

Gøtzsche P. C., Liberati A., Torri V., Rossetti L. Beware of Surrogate Outcome Measures // International journal of technology assessment in health care. 1996. Vol. 12. № 2. P. 238–246.

Hewlett S., De Wit M., Richards P., Quest E., Hughes R., Heiberg T., Kirwan J. Patients and professionals as research partners: Challenges, practicalities and benefits // Arthritis & Rheumatism. 2006. August 15. Vol. 55. № 4. P. 676–680.

Hewlett S., Cockshott Z., Byron M., Kitchen K., Tipler S., Pope D., Hehir M. Patients’ perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored // Arthritis & Rheumatism. 2005. October. Vol. 53. P. 697–702.

Hewlett S., Carr M., Ryan S., Kirwan J., Richards P., Carr A., Hughes R. Outcomes generated by patients with rheumatoid arthritis: how important are they? // Musculoskeletal care. 2005. Vol. 3. P. 131–142.

Rao J. K., Weinberger M., Kroenke K. Visit-specific expectations and patient-centered outcomes: a literature review // Archives of family medicine. 2000. November. Vol. 9. № 10. P. 1148–1155.

Sherine E. G., Sharon-Lise T. N. Getting the methods right – The foundation of patient-centered outcomes research // The New England journal of medicine. 2012. August. Vol. 367. № 9. P. 787–790.

Podolanczuk A. J., Lederer D. J. Patient-centered outcomes in idiopathic pulmonary fibrosis clinical trials // American Journal of Respiratory and Critical Care Medicine. 2017. September 15. Vol. 196. № 6. P. 674–675.

Lassere M. N., Johnson K. R., Boers M., Tugwell P., Brooks P., Simon L., Strand V. et al. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema // The Journal of rheumatology. 2007. March. Vol. 34. № 3. P. 607–615.

Hunter D. J., Losina E., Guermazi A., Burstein D., Lassere M. N., Kraus V. A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials // Current drug targets. 2010. May. Vol. 11. № 5. P. 536–545.

Chan A.-W., Hróbjartsson A., Haahr M. T. et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles // JAMA. 2004. May 26. Vol. 291. № 20. P. 2457–2465.

Lee K. L., McNeer J. F., Starmer C. F., Harris P. J., Rosati R. A. Clinical judgment and statistics. Lessons from a simulated randomized trial in coronary artery disease // Circulation. 1980. March. Vol. 61. № 3. P. 508–515.

Rothwell P. M. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation // Lancet. 2005. January. Vol. 365. P. 176–186.

Stallones R. A. The use and abuse of subgroup analysis in epidemiological research // Preventive medicine. 1987. March. Vol. 16. № 2. P. 183–194.

Oxman A. D., Guyatt G. H. A Consumer’s guide to subgroup analyses // Annals of internal medicine. 1992. January. Vol. 116. № 1. P. 78–84.

Sterne J. A. C., Smith G. D. Sifting the evidence – what’s wrong with significance tests? // Physical Therapy. 2001. August 1. Vol. 81. № 8. P. 1464–1469.

Guyatt G., Jaeschke R., Heddle N., Cook D., Shannon H., Walter S. Basic statistics for clinicians: 2. Interpreting study results: confidence intervals // Canadian Medical Association journal. 1995. January. Vol. 152. № 2. P. 169–173.

Kääriäinen I., Sipponen P., Siurala M. What fraction of hospital ulcer patients is eligible for prospective drug trials? // Scandinavian journal of gastroenterology. 1991. Vol. 26. № 186. P. 73–76.

Charlson M. E., Horwitz R. I. Applying results of randomised trials to clinical practice: impact of losses before randomisation // British medical journal. 1984. November 10. Vol. 289. P. 1281–1284.

Simpson S. H., Eurich D. T., Majumdar S. R., Padwal R. S., Tsuyuki R. T. et al. A meta-analysis of the association between adherence to drug therapy and mortality // BMJ. 2006. July 1. Vol. 333. № 7557.

Mitchell J. “But will it help my patients with myocardial infarction?” The implications of recent trials for everyday country folk // British Medical Journal. 1982. October 23. Vol. 285. P. 1140–1148.

Shepherd J. Statins for primary prevention: strategic options to save lives and money // Journal of the Royal Society of Medicine. 2004. February. Vol. 97. № 2. P. 66–71.

Asymptomatic Carotid Atherosclerosis Study Group. Carotid endarterectomy for patients with asymptomatic internal carotid artery stenosis // JAMA. 1995. Vol. 273. P. 1421–1428.

Moore W. S., Young B., Baker W. H. et al. Surgical results: a justification of the surgeon selection process for the ACAS trial // Journal of Vascular Surgery. 1996. Vol. 23. P. 323–328.

Bond R., Rerkasem K., Rothwell P. M. High morbidity due to endarterectomy for asymptomatic carotid stenosis // Cerebrovascular diseases. 2003. Vol. 16.

Vesper I. Europe’s academics fail to report results for 90% of clinical trials // Nature. 2018. September 13.

Plint A. C., Moher D., Morrison A., Schulz K., Altman D. G., Hill C., Gaboury I. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review // The Medical journal of Australia. 2006. September. Vol. 185. № 5. P. 263–267.

Rothstein H. R., Sutton A. J., Borenstein M. (eds). Publication Bias in Meta-analysis.

West Sussex, England: Wiley, 2005.

Tong C. H., Tong L.-I., Tong J. E. The Vioxx recall case and comments // Competitiveness Review. Vol. 19. № 2. P. 114–118.

Psaty B. M., Kronmal R. A. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation // JAMA. 2008. Vol. 299. № 15. P. 1813–1817.

Topol E. J. Failing the public health – rofecoxib, Merck, and the FDA // The New England journal of Medicine. 2004. October 21. Vol. 351. P. 1707–1709.

Berenson A. Evidence in Vioxx suits shows intervention by Merck officials // The New York Times. 2005. April 24.

Curfman G. D., Morrissey S., Drazen J. M. Expression of concern: Bombardier et al., “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis” // New England Journal of Medicine. 2000. Vol. 343. P. 1520–1528.

Egilman D. S., Presler A. H. Report of specific cardiovascular outcomes of the ADVANTAGE trial // Annals of internal medicine. 2006. May 16. Vol. 144. № 10. P. 781.

Nelson L. D. False-positives, p-hacking, statistical power, and evidential value. University of California, Berkeley, Haas School of Business, Summer Institute. 2014.

Dickersin K. How important is publication bias? A synthesis of available data // AIDS education and prevention. 1997. Vol. 9. P. 15–21.

Turner E. H., Matthews A. M., Linardatos E., Tell R. A., Rosenthal R. Selective publication of antidepressant. Trials and its influence on apparent efficacy // New England Journal of Medicine. 2008. Vol. 358. № 3. P. 252–260.

Rising K., Bacchetti P., Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation // Plos Medicine. 2008. November 25. Vol. 5. № 11, e217.

Scharf O., Colevas A. D. Adverse event reporting in publications compared with sponsor database for cancer clinical trials // Journal of clinical oncology. 2006. August 20. Vol. 24. № 24. P. 3933–3938.

MacLean C. H., Morton S. C., Ofman J. J., Roth E. A., Shekelle P. G. How useful are unpublished data from the Food and Drug Administration in meta-analysis? // Journal of clinical epidemiology. 2003. Vol. 56. P. 44–51.

Chan A.-W., Krleža-Jerić K., Schmid I., Altman D. G. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research // CMAJ. 2004. September 28. Vol. 171. № 7. P. 735–740.

Dwan K., Altman D. G., Arnaiz J. A., Bloom J., Chan A.-W., Cronin E. et al. Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias // PLOS One. 2008. August 28. Vol. 3. № 8, e3081.

Lee K. P., Boyd E. A., Holroyd-Leduc J. M., Bacchetti P., Bero L. A. Predictors of publication: characteristics of submitted manuscripts associated with acceptance at major biomedical journals // The Medical journal of Australia. 2006. June 19. Vol. 184. № 12. P. 621–626.

Ioannidis J., Lau J. Evolution of treatment effects over time: Empirical insight from recursive cumulative metaanalyses // PNAS. 2001. January 30. Vol. 98. № 3. P. 831–836.

Ross J. S., Mulvey G. K., Hines E. M., Nissen S. E., Krumholz H. M. Trial publication after registration in clinical trials. Gov: a cross-sectional analysis // Plos Medicine. 2009. September 8. Vol. 6. № 9, e1000144.

Drazen J. M., Wood A. J. J. Trial Registration Report Card // The New England journal of medicine. 2005. December 29. Vol. 353. P. 2809–2811.

Ioannidis J. P. A., Trikalinos T. A. Early extreme contradictory estimates may appear in published research: The Proteus phenomenon in molecular genetics researchand randomized trials // Journal of clinical epidemiology. 2005. Vol. 58. P. 543–549.

Ioannidis J. P. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials // JAMA. 1998. Vol. 279. № 4. P. 281–286.

Bekelman J. E., Li Y., Gross C. P. Scope and impact of financial conflicts of interest in biomedical research: a systematic review // JAMA. 2003. January 22–29. Vol. 289. № 4. P. 454–465.

Bhandari M., Busse J. W., Jackowski D., Montori V. M., Schünemann H. et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials // CMAJ. 2004. February 17. Vol. 170. № 4. P. 477–480.

Chalmers I. The true lorcainide story revealed // BMJ. 2015. Vol. 350, g7717

Cowley A. J., Skene A., Stainer K., Hampton J. R. The effect of lorcainide on arrhythmias and survival in patients with acute myocardial infarction: an example of publication bias // International journal of cardiology. 1993. July 1. Vol. 40. № 2. P. 161–166.

De Angelis C., Drazen J. M., Frizelle F. A., Haug C., Hoey J., Horton R. et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors // The New England journal of medicine. 2004. September 16. Vol. 351. P. 1250–1251.

Barroso C. Epistemology of medical knowledge / Seising R., Tabacchi M. (eds). Fuzziness and medicine: philosophical reflections and application systems in health care. Studies in fuzziness and soft computing. Vol. 302. Springer, Berlin, Heidelberg, 2013.

Eddy D. M. Evidence-based medicine: a unified approach // Health Affairs. 2005. Vol. 24. № 1. P. 9–17.

Claridge J. A., Fabian T. C. History and development of evidence-based medicine // World Journal of Surgery. 2005. Vol. 29. № 5. P. 547–553.

Van Baalen S. The epistemology of clinical decision-making: an epistemological analysis of reasoning in clinical practice, and the role of technological measurements. Master thesis. University of twente, 2014.

Goodman K. W. Ethics and evidence-based medicine. Fallibility and responsibility in clinical science. Cambridge University Press, 2002.

Glasziou P., Chalmers I., Rawlings M., McCulloch P. When are randomised trials unnecessary? Picking signal from noise // BMJ. 2007. Vol. 334. № 7589. P. 349–351.

Worrall J. Why There’s no cause to randomize // The British Journal for the Philosophy of Science. 2007. Vol. 58. № 3. P. 451–488.

Counsell C. E., Clarke M. J., Slattery J. et al. The miracle of DICE therapy for acute stroke: fact or fictional product of subgroup analysis? // BMJ. 1994. Vol. 309. P. 1677–1681.

Konstam M. A., Weir M. R., Reicin A., Shapiro D., Sperling R. S., Barr E., Gertz B. J. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib // Circulation. 2001. November 6. Vol. 104. № 19. P. 2280–2288.

De Leon J. Evidence-based medicine versus personalized medicine: are they enemies? // Journal of Clinical Psychopharmacology. 2012. April. Vol. 32. № 2. P. 153–164.

Ioannidis J. P. The mass production of redundant, misleading, and conflicted systematic reviews and meta-analyses // The Milbank quarterly. 2016. September. Vol. 94. № 3. P. 485–514.

Samet J. M. Epidemiology and the tobacco epidemic: how research on tobacco and health shaped epidemiology // American Journal of Epidemiology. 2016. March 1. Vol. 183. № 5. P. 394–402.

Cochrane A. Sickness in Salonica: my first, worst, and most successful clinical trial // British Medical Journal. 1984. December. Vol. 289. P. 1726–1727.

Simpson G. G. The therapiste and the researcher // Science. 1967. October 13. Vol. 158. № 3798. P. 246.

Cochrane A. L. Effectiveness and efficiency. London: Nuffield Provincial Hospitals Trust, 1972.

Stavrou A., Challoumas D., Dimitrakakis G. Archibald Cochrane (1909–1988): the father of evidence-based medicine // Interactive cardiovascular and thoracic surgery. 2014. January. Vol. 18. № 1. P. 121–124.

Barron A. B., Maleszka R., Helliwell P. G., Robinson G. E. Effects of cocaine on honey bee dance behaviour // The Journal of Experimental Biology. 2009. Vol. 212. P. 163–168.

Chan K. A clinical trial gone awry: the Chocolate Happiness Undergoing More Pleasantness (CHUMP) study // Canadian Medical Association journal. 2007. December 4. Vol. 177. № 12. P. 1539–1541.

Schwartz M. A. The importance of stupidity in scientific research // Journal of cell science. 2008. June 1. Vol. 121. № 11. P. 1771.

Shafik A. Effect of different types of textiles on sexual activity. Experimental study // European urology. 1993. Vol. 24. № 3. P. 375–380.

Crowley P., Chalmers I., Keirse M. J. N. The effects of corticosteroid administration before preterm delivery: an overview of the evidence from controlled trials // British Journal of Obstetrics & Gynaecology. 1990. January. Vol. 97. № 1. P. 11–25.

Olson M. V. Precision medicine at the crossroads // Human genomics. 2017. Vol. 11. P. 23.

Windsor B., Popovich I., Jordan V., Showell M., Shea B., Farquhar C. Methodological quality of systematic reviews in subfertility: a comparison of Cochrane and non-Cochrane systematic reviews in assisted reproductive technologies // Human reproduction. 2012. December. Vol. 27. № 12. P. 3460–3466.

Fleming P. S., Seehra J., Polychronopoulou A., Fedorowicz Z., Pandis N. Cochrane and non-Cochrane systematic reviews in leading orthodontic journals: a quality paradigm? // The European Journal of Orthodontics. 2013. April. Vol. 35. № 2. P. 244–248.

Moseley A. M., Elkins M. R., Herbert R. D., Maher C. G., Sherrington C. Cochrane reviews used more rigorous methods than non-Cochrane reviews: survey of systematic reviews in physiotherapy // Journal of clinical epidemiology. 2009. October. Vol. 62. № 10. P. 1021–1030.

Olsen O., Middleton P., Ezzo J. et al. Quality of Cochrane reviews: assessment of sample from 1998 // BMJ. 2001. October. Vol. 323. № 7317. P. 829–832.

Clarke M., Chalmers I. Discussion sections in reports of controlled trials published in general medical journals // JAMA. 1998. Vol. 280. № 3. P. 280–282.

Clarke M., Hopewell S., Chalmers I. Reports of clinical trials should begin and end with up-to-date systematic reviews of other relevant evidence: a status report // Journal of the Royal Society of Medicine. 2007. April. Vol. 100. P. 187–190.

Fergusson D., Glass K. C., Hutton B., Shapiro S. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? // Clinical Trials. 2005. June 1. Vol. 2. № 3. P. 218–232.

LeLorier J., Grégoire G., Benhaddad A., Lapierre J., Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials // The New England Journal of Medicine. 1997. August 21. Vol. 337. № 8. P. 536–542.

Amanullah S., Venkataraman R. The routine use of albumin for fluid resuscitation of critically ill patients is not warranted // Critical Care. 2004. December. Vol. 8. № 6.

Sauerland S., Maegele M. A CRASH landing in severe head injury // Lancet. 2004. October 9. Vol. 364. № 9442. P. 1291–1292.

Mirza R. D., Punja S., Vohra S., Guyatt G. The history and development of N of 1 trials // Journal of the Royal Society of Medicine. 2017. Vol. 110. № 8. P. 330–340.

Ioannidis J. P. A., Khoury M. J. Evidence-based medicine and big genomic data // Human Molecular Genetics. 2018. May 1. Vol. 27. № R 1. P. R2–7.

Lillie E. O., Patay B., Diamant J., Issell B., Topol E. J., Schork N. J. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? // Personalized medicine. 2011. March. Vol. 8. № 2. P. 161–173.

Moore A., Derry S., Eccleston C., Kalso E. Expect analgesic failure; pursue analgesic success // BMJ. 2013. Vol. 346. № 7911, f2690.

Wegman A., Van der Windt D. A., De Haan M., Deville W., Fo C., de Vries T. P. Switching from NSAIDs to paracetamol: a series of n of 1 trials for individual patients with osteoarthritis // Annals of the rheumatic diseases. 2003. December. Vol. 62. № 12. P. 1156–1161.

Mahon J. L., Laupacis A., Hodder R. V., McKim D. A., Paterson N. A., Wood T. E. et al. Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice // Chest. 1999. January. Vol. 115. № 1. P. 38–48.

Pope J. E., Prashker M., Anderson J. The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis // The Journal of Rheumatology. 2004. January. Vol. 31. № 1. P. 140–149.

Ledford H. Cancer-genome study challenges mouse “avatars” // Nature. 2017. October 9.

Lai Y., Wei X., Lin S., Qin L., Cheng L., Li P. Current status and perspectives of patient-derived xenograft models in cancer research // Journal of Hematology & Oncology. 2017. Vol. 10. P. 106.

Ferriss J. S., Rice L. W. The role of in vitro directed chemotherapy in epithelial ovarian cancer // Reviews in obstetrics & gynecology. 2010. Spring. Vol. 3. № 2. P. 49–54.

Burstein H. J., Mangu P. B., Somerfield M. R., Schrag D., Samson D., Holt L. et al. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays // Journal of clinical oncology. 2011. August 20. Vol. 29. № 24. P. 3328–3330.

Gebelhoff R. Sequencing the genome creates so much data we don’t know what to do with it // The Washington Post. 2015. July 7.

Goetz M. P., Kamal A., Ames M. M. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response // Clinical pharmacology and therapeutics. 2008. January. Vol. 83. № 1. P. 160–166.

Rubin R. Precision medicine: the future or simply politics? // JAMA. 2015. Vol. 313. № 11. P. 1089–1091.


Часть шестая

Lindsay G. B., Merrill R. M., Hedin R. J. The contribution of public health and improved social conditions to increased life expectancy: an analysis of public awareness // Journal of Community Medicine and Health Education. 2014. Vol. 4. P. 311.

Ten great public health Achievements – United States, 1900–1999 // MMWR. 1999. April 2. Vol. 48. № 12. P. 241–243.

Bunker J. P., Frazier H. S., Mosteller F. Improving health: measuring effects of medical care // The Milbank quarterly. 1994. Vol. 72. № 2. P. 225–258.

McKinley J. B., McKinley S. M. The questionable contribution of medical measures to the decline of mortality in the United States in the twentieth century // The Milbank Memorial Fund quarterly. Health and society. 1977. Summer. Vol. 55. № 3. P. 405–428.

Bunker J. P. The role of medical care in contributing to health improvements within societies // International Journal of Epidemiology. 2001. December 1. Vol. 30. № 6. P. 1260–1263.

Murray C. J. L. Why is Japanese life expectancy so high? // Lancet. 2011. September 24. Vol. 378. № 9797. P. 1124–1125.

Shiro Horiuchi Major causes of the rapid longevity extension in postwar Japan // The Japanese Journal of Population. 2011. March. Vol. 9. № 1. P. 162–171.

Crimmins E. M., Preston S. H., Cohen B. (eds) Explaining divergent levels of longevity in high-income countries. Washington (DC): National Academies Press (US), 2011.

Marmot M. G. Status syndrome: A challenge to medicine // JAMA. 2006. Vol. 295. № 11. P. 1304–1307.

Marmot M. The status syndrome: How social standing affects our health and longevity. New York, NY: Henry Holt and Company, 2004.

Marmot M. G., Rose G., Shipley M., Hamilton P. J. S. Employment grade and coronary heart disease in British civil servants // Journal of epidemiology and community health. 1978. Vol. 32. № 4. P. 244–249.

Adler N., Ostrove J. Socioeconomic status and health: what we know and what we don’t /Adler N., Marmot M., McEwen B., Stewart J. (eds.) Socioeconomic status and health in industrial nations. New York, NY: New York Academy of Sciences, 1999. P. 3–15.

Mackenbach J. P., Bos V., Andersen O. et al. Widening socioeconomic inequalities in mortality in six Western European countries // International Journal of Epidemiology. 2003. Vol. 32. P. 830–837.

McDonough P., Duncan G. J., Williams D., House J. S. Income dynamics and adult mortality in the United States, 1972 through 1989 // The American Journal of Public Health. 1997. Vol. 87. № 9. P. 1476–1483.

Britton A., Shipley M., Marmot M., Hemingway H. Does access to cardiac investigation and treatment contribute to social and ethnic differences in coronary heart disease? Whitehall II prospective cohort study // BMJ. 2004. Vol. 329. № 7461. P. 318–323.

Closing the gap in a generation: health equity through action on the social determinants of health. Final Report of the Commission on Social Determinants of Health. Geneva, World Health Organization, 2008.

Franco Á., Álvarez-Dardet C., Ruiz M. T. Effect of democracy on health: ecological study // BMJ. 2004. December 18. Vol. 329. № 7480. P. 1421–1423.

Johanson R., Newburn M., Macfarlane A. Has the medicalisation of childbirth gone too far? // BMJ. 2002. Vol. 324. № 7342. P. 892–895.

Kaunitz A. M., Spence C., Danielson T. S., Rochat R. W., Grimes D. A. Perinatal and maternal mortality in a religious group avoiding obstetric care // American Journal of Obstetrics & Gynecology. 1984. December 1. Vol. 150. № 7. P. 826–831.

Stamatakis E., Weiler R., Ioannidis J. P. Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review // European journal of clinical investigation. 2013. Vol. 43. № 5. P. 469–475.

Moynihan R., Doran E., Henry D. Disease mongering is now part of the global health debate // PLoS Medicine. 2008. Vol. 5. № 5, e106.

Simons J. The $ 10 Billion Pill Hold the fries, please. Lipitor, the cholesterol-lowering drug, has become the bestselling pharmaceutical in history. Here’s how Pfizer did it // Fortune. 2003. January 20. Vol. 147. № 1. P. 58–62.

Лечение ОРВИ и гриппа в рутинной клинической практике // Фармацевтический вестник. 2017. 28 июля.

Мизерницкий Ю. Л. Применение инновационного отечественного индуктора интерферона для профилактики и лечения острых респираторных вирусных инфекций у детей // Медицинский совет. 2016. № 1. С. 50–53.

Харламова Ф. С., Кладова О. В., Сергеева Э. М. и др. Клиническая эффективность препарата Кагоцел® при гриппе и ОРВИ у детей с 2 до 6 лет // Детские инфекции. 2010. № 4. С. 34–41.

Вартанян Р. В., Сергеева Э. М., Чешик С. Г. Оценка терапевтической эффективности препарата Кагоцел® у детей младшего и дошкольного возраста с острыми респираторными вирусными инфекциями // Детские инфекции. 2011. № 1. С. 36–41.

Hill K. P., Ross J. S., Egilman D. S., Krumholz H. M. The ADVANTAGE seeding trial: A review of internal documents // Annals of Internal Medicine. 2008. Vol. 149. № 4. P. 251–258.

Krimsky S., Rothenberg L. S., Stott P., Kyle G. Scientific journals and their authors’ financial interests: A pilot study // Psychotherapy and psychosomatics. 1998. July-October. Vol. 67. № 4–5. P. 194–201.

Papanikolaou G. N., Baltogianni M. S., Contopoulos-Ioannidis D. G. et al. Reporting of conflicts of interest in guidelines of preventive and therapeutic interventions // BMC medical research methodology. 2001. Vol. P. 3.

Sismondo S. Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? // PLoS Medicine. 2007. Vol. 4. № 9, e286.

Mirowski P., Van Horn R. The contract research organization and the commercialization of scientific research // Social studies of science. 2005. August. Vol. 35. № 4. P. 503–548.

Gubler A. Alternating hemiplegia, a sign of pontine lesion, and documentation of the proof of the facial decussation / Wolf J. K. (ed.). The Classical Brainstem Syndromes. Springfield: Charles C Thomas, 1971. P. 9–13.

Austin S. C., Stolley P. D., Lasky T. The history of malariotherapy for neurosyphilis // JAMA. 1992. Vol. 268. № 4. P. 516–519.

Valenstein E. S. Great and desparate cures: The rise and decline of psychosurgery and other radical treatments for mental illness. New York: Basic Books, 1986.

EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial // The New England journal of medicine. 1985. November 7. Vol. 313. № 19. P. 1191–1200.

Echt D. S., Liebson P. R., Mitchell L. B. et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Supression Trial // The New England journal of medicine. 1991. March 21. Vol. 324. № 12. P. 781–788.

Moore T. J. Deadly Medicine: Why tens of thousands of heart patients died in america’s worst drug disaster. New York: Simon and Schuster, 1995.

Teo K. K., Yusuf S., Furberg C. D. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized trials // JAMA. 1993. October 6. Vol. 270. № 13. P. 1589–1595.

Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? // Lancet. 1995. June 10, Vol. 345. № 8963. P. 1455–1463.

Morgan D. J., Brownlee S., Leppin A. L., Kressin N., Dhruva S. S., Levin L. et al. Setting a research agenda for medical overuse // BMJ. 2015. August 25. Vol. 351. № 1, h4534.

Spencer I. Lessons from history: the politics of psychiatry in the USSR // Journal of Psychiatric and Mental Health Nursing. 2000. August. Vol. 7. № 4. P. 355–361.

Bloch S. Psychiatry as ideology in the USSR // Journal of medical ethics. 1978. Vol. 4. P. I26–13I.

Cochrane A. L., St Leger A. S., Moore F. Health service ‘input’ and mortality ‘output’ in developed countries // Journal of epidemiology and community health. 1978. September. Vol. 32. № 3. P. 200–205.

Carr-Hill R. A., Hardman G. F., Russell I. T. Variations in avoidable mortality and variations in health care resources // Lancet. 1987. April 4. Vol. 1. № 8536. P. 789–792.

Metcalfe D., Chowdhury R., Salim A. What are the consequences when doctors strike? // BMJ. 2015. November 25. Vol. 351. № 8035, h6231.

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 // Lancet. 2015. January 10. Vol. 385. № 9963. P. 117–171.

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 // Lancet. 2015. August 22. Vol. 386. № 9995. P. 743–800.

Kelly W. N. Can the frequency and risks of fatal adverse drug events be determined? // Pharmacotherapy. 2001. May. Vol. 21. № 5. P. 521–527.

Lazarou J., Pomeranz B. H., Corey P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analyses of prospective studies // JAMA. 1998. April 15. Vol. 279. № 15. P. 1200–1205.

Starfield B. Is US health really the best in the world? // JAMA. 2000. July 26. Vol. 284. № 4. P. 483–485.

Phillips D. P., Christenfeld N., Glynn L. M. Increase in US medication-error deaths between 1983 and 1993 // Lancet. 1998. February 28. Vol. 351. № 9103. P. 643–644.

Klevens R. M., Edwards J. R., Richards C. L., Horan T. C., Gaynes et al Estimating healthcare-associated infections and deaths in U. S. hospitals, 2002 // Public Health Reports. 2007. March-April. Vol. 122. № 2. P. 160–166.

Ernst F. R., Grizzle A. J. Drug-related morbidity and mortality: updating the cost-of-illness model // Journal of the American Pharmaceutical Association. 2001. March/April. Vol. 41. № 2. P. 192–199.

Johnson J. A., Boatman L. Drug-related morbidity and mortality: A Cost-of-illness model // Journal of Managed Care Pharmacy. 1996. January/February. Vol. 2. № 1. P. 39–47.

Sturkenboom M. C., Romano F., Simon G., Correa-Leite M. L., Villa M. et al. The iatrogenic costs of NSAID therapy: a population study // Arthritis and rheumatism. 2002 April 15. Vol. 47. № 2. P. 132–140.

Weingart S. N., Wilson R. McL., Gibberd R. W., Harrison B. Epidemiology of medical error // BMJ. 2000. March 18. Vol. 320. № 7237. P. 774–777.

Hayward R. A., Hofer T. P. Estimating hospital deaths due to medical errors: preventability is in the eye of the reviewer // JAMA. 2001. Vol. 286. № 4. P. 415–420.

Feldman H. A., Goldstein I., Hatzichristou D. G., Krane R. J., McKinlay J. B. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study // The Journal of urology. 1994. January. Vol. 151. № 1. P. 54–61.

Araujo A. B., Johannes C. B., Feldman H. A., Derby C. A., McKinlay J. B. Relation between psychosocial risk factors and incident erectile dysfunction: prospective results from the Massachusetts male aging study // American Journal of Epidemiology. 2000. September 15. Vol. 152. № 6. P. 533–541.

Lexchin J. Bigger and better: how Pfizer redefined erectile dysfunction // PLoS Medicine. 2006. Vol. 3. № 4, e132.

Sample I. Viagra: The profitable pill // The Guardian. 2009. November 16.

Moynihan R. The making of a disease: female sexual dysfunction // BMJ. 2003. January 4. Vol. 326. № 7379. P. 45–47.

Critser G. Generation Rx: How prescription drugs are altering American lives, minds, and bodies. Boston: Houghton-Mifflin, 2005.

Laumann E. O., Paik A., Rosen R. C. Sexual dysfunction in the United States: prevalence and predictors // JAMA. 1999. Vol. 281. № 6. P. 537–544.

Moynihan R., Heath I., Henry D. Selling sickness: the pharmaceutical industry and disease mongering // BMJ. 2002. April 13. Vol. 324. № 7342. P. 886–891.

Clark D. Between hope and acceptance: the medicalisation of dying // BMJ. 2002. April 13. Vol. 324. № 7342. P. 905–907.

Gilbert D., Walley T., New B. Lifestyle medicines // BMJ. 2000. November 25. Vol. 321. № 7272. P. 1341–1344.

Maggini M., Vanacore N., Raschetti R. Cholinesterase inhibitors: drugs looking for a disease? // PLoS Medicine. 2006. Vol. 3. № 4, e140.

Phillips C. B. Medicine goes to school: Teachers as sickness brokers for ADHD // PLoS Medicine. 2006. Vol. 3. № 4, e182.

Healy D. The latest mania: Selling bipolar disorder // PLoS Medicine. 2006. Vol. 3. № 5, e236.

Scott S. The medicalisation of shyness: from social misfits to social fitness // Sociology of Health & Illness. 2006. Vol. 28. № 2. P. 133–153.

Wolinsky H. Disease mongering and drug marketing // EMBO reports 2005. Vol. 6. № 7. P. 612–614.

Woloshin S., Schwartz L. M. Giving legs to restless legs: A case study of How the media helps make people sick // PLoS Medicine. 2006. Vol. 3. № 4, e170.

Gagnon M.-A., Lexchin J. The cost of pushing pills: A new estimate of pharmaceutical promotion expenditures in the United States // PLoS Medicine. 2008. Vol. 5. № 1, e1.

Branding the cure: a consumer perspective on corporate social responsibility, drug promotion and the pharmaceutical industry in Europe. London: Consumers International, 2006.

Matheson A. The disposable author: how pharmaceutical marketing is embraced within medicine’s scholarly literature // Hastings Center Report. 2016. July/August. Vol. 46. № 4. P. 31–37.

Giannakakis I. A., Ioannidis J. P. A. Arabian nights – 1001 tales of how pharmaceutical companies cater to the material needs of doctors: case report // BMJ. 2000. December 23. Vol. 321. № 7276. P. 1563–1564.

Donohue J. M., Cevasco M., Rosenthal M. B. A decade of direct-to-consumer advertising of prescription drugs // The New England journal of medicine. 2007. Vol. 357. № 7. P. 673–681.

Applbaum K. Is marketing the enemy of pharmaceutical innovation? // Hastings Center Report. 2009. July-August. Vol. 39. № 4. P. 13–17.

Ioannidis J. P. A. Mega-trials for blockbusters // JAMA. 2013. January 16. Vol. 309. № 3. P. 239–240.

Moffatt B., Elliott C. Ghost marketing: pharmaceutical companies and ghostwritten journal articles // Perspectives in Biology and Medicine. 2007.·February. Vol. 50. № 1. P. 18–31.

Goldbloom D. S. Physicians and the pharmaceutical industry // CPA Bulletin de l’APC. 2003. October. P. 3–4.

Goldbloom D. S. Les médecins et l’industrie pharmaceutique // CPA Bulletin de l’APC. 2003. October. P. 4–5.

Wazana A. Physicians and the pharmaceutical industry. Is a gift ever just a gift? // JAMA. 2000. Vol. 283. № 3. P. 373–380.

Orlowski J. P., Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch // Chest. 1992. Vol. 102. № 270–273.

Grande D., Frosch D. L., Perkins A. W., Kahn B. E. Effect of exposure to small pharmaceutical promotional items on treatment preferences // Archives of Internal Medicine. 2009. Vol. 169. № 9. P. 887–893.

Gilbody S., Wilson P., Watt I. Benefits and harms of direct to consumer advertising: a systematic review // BMJ Quality & Safety. 2005. Vol. 14. P. 246–250.

Frosch D. L., Krueger P. M., Hornik R. C., Cronholm P. F., Barg F. K. Creating demand for prescription drugs: a content analysis of television direct-to-consumer advertising // Annals of family medicine. 2007. January-February. Vol. 5. № 1. P. 6–13.

Ventola C. L. Direct-to-consumer pharmaceutical advertising. Therapeutic or Toxic? // P & T: a peer-reviewed journal for formulary management. 2011. October. Vol. 36. № 10. P. 669–684.

Frosch D. L., Grande D., Tarn D. M., Kravitz R. L. A decade of controversy: balancing policy with evidence in the regulation of prescription drug advertising // American journal of public health. 2010. January. Vol. 100. № 1. P. 24–32.

Experimental evaluation of the impact of distraction on consumer understanding of risk and benefit information in direct-to-consumer prescription drug television advertisements. 2011. June.

Grimes T. Mild auditory-visual dissonance in television news may exceed viewer attentional capacity // Human Communication Research. 1991. December 1. Vol. 18. № 2. P. 268–298.

Kravitz R. L., Epstein R. M., Feldman M. D., Franz C. E., Azari R. et al. Influence of patients’ requests for direct-to-consumer advertised antidepressants: a randomized controlled trial // JAMA. 2005. April 27. Vol. 293. № 16. P. 1995–2002.

Mintzes B., Barer M. L., Kravitz R. L., Kazanjian A., Bassett K., Lexchin J. et al. Influence of direct to consumer pharmaceutical advertising and patients’ requests on prescribing decisions: two site cross sectional survey // British Medical Journal. 2002. Vol. 324. № 7332. P. 278–279.

Hochhauser M. Is this a seeding trial? // Journal of Clinical Research Best Practices. 2009. June. Vol. 5. № 6.

Vedula S. S., Bero L., Scherer R. W., Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use // The New England Journal of Medicine. 2009. № 20. Vol. 361. P. 1963–1971.

Sox H. C., Rennie D. Seeding trials: just say “No” // Annals of Internal Medicine (Editorial). 2008. August 19. Vol. 149. № 4. P. 279–280.

Kuriya B., Schneid E. C., Bell C. M. Quality of pharmaceutical industry press releases based on original research // PLoS ONE. 2008. Vol. 3. № 7, e2828.

Woloshin S., Schwartz L. M. Press releases: translating research into news // JAMA. 2002. Vol. 287. № 21. P. 2856–2858.

Yavchitz A., Boutron I., Bafeta A., Marroun I., Charles P., Mantz J. et al. Misrepresentation of randomized controlled trials in press releases and news coverage: a cohort study // PLoS Med. 2012. Vol. 9. № 9, e1001308.

Welch H. G., Black W. C. Overdiagnosis in Cancer // Journal of the National Cancer Institute. 2010. May 5. Vol. 102. № 9. P. 605–613.

Барчук А., Талантов П. Война на опережение. Скрининг не станет очередной панацеей от рака, нужно менять привычки людей // Новая газета. 2018. 17 сентября. № 102.

Marmot M. G., Altman D. G., Cameron D. A., Dewar J. A., Thompson S. G., Wilcox M. The benefits and harms of breast cancer screening: an independent review // British Journal of Cancer. 2013. June 11. Vol. 108. № 11. P. 2205–2240.

Gøtzsche P. C., Nielsen M. Screening for breast cancer with mammography (Review). Cochrane Database of Systematic Reviews. 2011. № 4.

Yaffe M. J., Mainprize J. G. Risk of radiation-induced breast cancer from mammographic screening // Radiology. 2011. January. Vol. 258. № 1. P. 98–105.

WHO position paper on mammography screening. World Health Organization, 2014.

Schroder F. H., Hugosson J., Roobol M. J. et al. Screening and prostate-cancer mortality in a randomized european study // The New England Journal of Medicine. 2009. Vol. 360. № 13. P. 1320–1328.

Draisma G., Boer R., Otto S. J. et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer // Journal of the National Cancer Institute. 2003. June 18. Vol. 95. № 12. P. 868–878.

Gillies D. Hempelian and Kuhnian approaches in the philosophy of medicine: the Semmelweis Case // Studies in history and philosophy of biological and biomedical sciences. 2005. March. Vol. 36. № 1. P. 159–181.

Noakes T. D., Borresen J., Hew-Butler T., Lambert M. I., Jordaan E. Semmelweis and the aetiology of puerperal sepsis 160 years on: an historical review // Epidemiology and infection. 2008. January. Vol. 136. № 1. P. 1–9.

Dunn P. M. Ignac Semmelweis (1818–1865) of Budapest and the prevention of puerperal fever // Archives of disease in childhood. Fetal and neonatal edition. 2005. Vol. 90. № 4, F345–348.

Semmelweis I. The etiology, concept, and prophylaxis of childbed fever. Madison and London: The University of Wisconsin Press, 1983.

Best M., Neuhauser D. Ignaz Semmelweis and the birth of infection control // Quality & safety in health care. 2004. June. Vol. 13. № 3. P. 233–234.

Bridson E. Y. Iatrogenic epidemics of puerperal fever in the 18th and 19th centuries // British journal of biomedical science. 1996. June. Vol. 53. № 2. P. 134–139.

Alper B. S., Hand J. A., Elliott S. G., Kinkade S., Hauan M. J., Onion D. K. et al. How much effort is needed to keep up with the literature relevant for primary care? // Journal of the Medical Library Association. 2004. October. Vol. 92. № 4. P. 429–437.

Neuman J., Korenstein D., Ross J. S., Keyhani S. Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study // BMJ. 2011. Vol. 343. № 7827, d5621.

Khan R., Scaffidi M. A., Rumman A., Grindal A. W., Plener I. S., Grover S. C. Prevalence of financial conflicts of interest among authors of clinical guidelines related to high-revenue medications // JAMA Internal Medicine. 2018. Vol. 178. № 12. P. 1712–1715.

Combs T. R., Scott J., Jorski A., Heavener T., Vassar M. Evaluation of industry relationships among authors of clinical practice guidelines in gastroenterology // JAMA Internal Medicine. 2018. Vol. 178. № 12. P. 1711–1712.

McAlister F. A., Van Diepen S., Padwal R. S., Johnson J. A., Majumdar S. R. How evidence-based are the recommendations in evidence-based guidelines? // Plos Medicine. 2007. Vol. 4. № 8, e250.

Marciano N. J., Merlin T. L., Bessen T., Street J. M. To what extent are current guidelines for cutaneous melanoma follow up based on scientific evidence? // International journal of clinical practice. 2014. June. Vol. 68. № 6. P. 761–770.

De Blois J., Fagerland M. W., Grundtvig M., Semb A. G., Gullestad L.et al. ESC guidelines adherence is associated with improved survival in patients from the Norwegian Heart Failure Registry // European Heart Journal. Cardiovascular Pharmacotherapy. 2015. January 1. Vol. 1. № 1. P. 31–36.

Tsugawa Y., Newhouse J. P., MacArthur J. D., Zaslavsky A. M. et al. Physician age and outcomes in elderly patients in hospital in the US: observational study // BMJ. 2017. Vol. 357. № 8106, j1797.

Nooh A., Baghdadi S., Raouf S. Induction of labour: how close to the evidence-based guidelines are we? // Journal of Obstetrics and Gynaecology. 2005. Vol. 25. № 5. P. 451–454.

Kondov K.; Sharpe P.; Mousa H. Are we following the guidelines – a retrospective analysis of compliance with evidence based protocols in cases admitted to Intensive Care Unit (ICU) from Labour Ward (LW): 1AP2–2 // European Journal of Anaesthesiology. 2012. June. Vol. 29. P. 9.

Holmes J. S., Shevrin M., Goldman, B., Share D. Translating research into practice: are physicians following evidence-based guidelines in the treatment of hypertension? // Medical Care Research and Review. 2004. Vol. 61. № 4. P. 453–473.

Gabbay J., Le May A. Evidence based guidelines or collectively constructed “mindlines”? Ethnographic study of knowledge management in primary care // BMJ. 2004. October 30. Vol. 329. № 7473. P. 1013–1018.

André M., Borgquist L., Foldevi M., Mölstad S. Asking for ‘rules of thumb’: a way to discover tacit knowledge in general practice // Family practice. 2002. December. Vol. 19. № 6. P. 617–622.

André M., Borgquist L., Mölstad S. Use of rules of thumb in the consultation in general practice – an act of balance between the individual and the general perspective // Family practice. 2003. October. Vol. 20. № 5. P. 514–519.

Зайцева Е. А. Клинический выбор врачей в крупном российском городе: опыт качественного анализа // Медицинская антропология и биоэтика. 2018. Т. 1. № 15.

Hajjaj F. M., Salek M. S., Basra M. K. A., Finlay A. Y. Non-clinical influences on clinical decision-making: a major challenge to evidence-based practice // Journal of the Royal Society of Medicine. 2010. May 1. Vol. 103. № 5. P. 178–187.

Bernheim S. M., Ross J. S., Krumholz H. M., Bradley E. H. Influence of patients’ socioeconomic status on clinical management decisions: a qualitative study // Annals of family medicine. 2008. January. Vol. 6. № 1. P. 53–59.

Arie S. Ending the French love affair with drugs // BMJ. 2012. Vol. 345. № 7879, e6996.

Prasad V., Vandross A., Toomey C., Cheung M., Rho J., Quinn S. et al. A decade of reversal: an analysis of 146 contradicted medical practices // Mayo Clinic proceedings. 2013. August. Vol. 88. № 8. P. 790–798.

Garrow J. S. How much of orthodox medicine is evidence based? // BMJ. 2007. Vol. 335. № 7627. P. 951.

Меркулова Л. Н. Колобухина Л. В., Кистенева Л. Б. и др. Терапевтическая эффективность Кагоцела при лечении больных не осложненным гриппом и гриппом, осложненным ангиной // Клиническая фармакология и терапия. 2002. Т. 11. № 6. С. 21–23.

Фазылов В. Х., Ситников И. Г., Силина Е. В., Шевченко С. Б., Можина Л. Н. и др. Лечение больных ОРВИ и гриппом в повседневной клинической практике (результаты многоцентрового международного наблюдательного исследования FLU-EE) // Терапевтический архив. 2016. Т. 88. № 11. С. 68–75.

Алиферова В. М., Дадашева М. Н., Доронин Б. М., Коваленко А. В. и др. Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта // Журнал неврологии и психиатрии им. С. С. Корсакова. 2014. Т. 114. № 4. С. 41–46.

Howes N., Chagla L., Thorpe M., McCulloch P. Surgical practice is evidence based // The British journal of surgery. 1997. September. Vol. 84. № 9. P. 1220–1223.

Kehlet H., Wilmore D. W. Multimodal strategies to improve surgical outcome // The American Journal of Surgery. 2002. Vol. 183. P. 630–641.

Kehlet H., Dahl J. B. Anaesthesia, surgery, and challenges in postoperative recovery // Lancet. 2003. Vol. 362. P. 1921–1928.

Wartolowska K., Judge A., Hopewell S., Collins G. S., Dean B. J. F. et al. Use of placebo controls in the evaluation of surgery: systematic review // BMJ. 2014. Vol. 348. № 7960, g3253.

Solomon M. J., Laxamana A., Devore L., McLeod R. S. Randomized controlled trials in surgery // Surgery. 1994. June 1. Vol. 115. № 6. P. 707–712.

Cobb L. A., Thomas G. I., Dillard D. H., Merendino K. A., Bruce R. A. An evaluation of internal-mammary-artery ligation by a double-blind technic // The New England Journal of Medicine. 1959. May 28. Vol. 260. № 22. P. 1115–1118.

Siemieniuk R. A. C., Harris I. A., Agoritsas T., Poolman R. W. et al. Arthroscopic surgery for degenerative knee arthritis and meniscal tears: a clinical practice guideline // BMJ. 2017. Vol. 357. № 8105, j1982.

Freed C. R., Greene P. E., Breeze R. E., Tsai W. Y., DuMouchel W., Kao R. et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease // The New England journal of medicine. 2001. March 8. Vol. 344. № 10. P. 710–719.

Tsugawa Y., Jena A. B., Newhouse R. L., Orav E. J., Blumenthal D. M. et al. Age and sex of surgeons and mortality of older surgical patients: observational study // BMJ. 2018. Vol. 361. № 8150, k1343.

Papanikolaou P. N., Churchill R., Wahlbeck K., Ioannidis J. P. A. Safety reporting in randomized trials of mental health interventions // American Journal of Psychiatry. 2004. Vol. 161. P. 1692–1697.

Smith M. L., Glass G. V. Meta-analysis of psychotherapy outcome studies // The American psychologist. 1977. September. Vol. 32. № 9. P. 752–760.

Landman J. T., Dawes R. M. Psychotherapy outcome: Smith and Glass’ conclusions stand up under scrutiny // American Psychologist. 1982. Vol. 37. № 5. P. 504–516.

Luborsky L., Singer B., Luborsky L. Comparative studies of psychotherapies: is it true that “Everyone has won and all must have prizes”? // Archives of General Psychiatry. 1975. Vol. 32. № 8. P. 995–1008.

Strupp H. H., Hadley S. W. Specific vs nonspecific factors in psychotherapy. A controlled study of outcome // Archives of general psychiatry. 1979. September. Vol. 36. № 10. P. 1125–1136.

Bootzin R. R., Bailey E. T. Understanding placebo, nocebo, and iatrogenic treatment effects // Journal of clinical psychology. 2005. July. Vol. 61. № 7. P. 871–880.

Butler A. C., Chapman J. E., Forman E. M., Beck A. T. The empirical status of cognitive-behavioral therapy: A review of meta-analyses // Clinical Psychology Review. 2006. Vol. 26. P. 17–31.

Tolin D. F. Is cognitive-behavioral therapy more effective than other therapies? A meta-analytic review // Clinical Psychology Review. Vol. 30. № 6. P. 710–720.

Barth J., Munder T., Gerger H., Nüesch E., Trelle S., Znoj H. et al. Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis // PLoS Med. 2013. Vol. 10. № 5, e1001454.

Mayo-Wilson E., Dias S., Mavranezouli I., Kew K. et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis // Lancet Psychiatry. 2014. Vol. 1. № 5. P. 368–376.

Marcus D. K., O’Connell D., Norris A. L., Sawaqdeh A. Is the Dodo bird endangered in the 21st century? A meta-analysis of treatment comparison studies // Clinical Psychology Review. 2014. November. Vol. 34. № 7. P. 519–530.

Wampold B. E., Flückiger C., Del Re A. C., Yulish N. E., Frost N. D., Pace B. T. et al In pursuit of truth: A critical examination of meta-analyses of cognitive behavior therapy // Psychotherapy Research. 2017. Vol. 27. № 1. P. 14–32.

Van Emmerik A. A. P., Kamphuis J. H, Hulsbosch A. M., Emmelkamp P. M. G. Single session debriefing after psychological trauma: a meta-analysis // Lancet. 2002. September 07. Vol. 360. № 9335. P. 766–771.

Rose S., Brewin C. R., Andrews B., Kirk M. A randomized controlled trial of individual psychological debriefing for victims of violent crime // Psychological Medicine. 1999. July. Vol. 29. № 4. P. 793–799.

Roberts N. P., Kitchiner N. J., Kenardy J., Bisson J. I. Multiple session early psychological interventions for the prevention of posttraumatic stress disorder // Cochrane Database of Systematic Reviews. 2009. № 3. Art. № CD006869. Coulter I. D., Willis E. M. The rise and rise of complementary and alternative medicine: a sociological perspective // MJA. 2004. June 7. Vol. 180. P. 587–589.

Sampson W. Antiscience trends in the rise of the “alternative medicine” movement // Annals of the New York Academy of Sciences. 1996. June 24. Vol. 775. P. 188–197.

Eisenberg D. M., Davis R. B., Ettner S. L. et al. Trends in alternative medicine use in the United States, 1990–1997 // JAMA. 1998. Vol. 280. № 18. P. 1569–1575.

Murray J., Shepherd S. Alternative or additional medicine? An exploratory study in general practice // Social science & medicine. 1993. Vol. 37. № 8. P. 983–988.

Homeopathic Medicine & Advertising: An FTC Workshop Comments of the American Association of Homeopathic Pharmacists. 2015. November 20.

DSM Group: гомеопатические препараты занимают менее 1% рынка лекарств России // Фармацевтический вестник. 2017. 6 февраля.

Mathie R. T., Frye J., Fisher P. Homeopathic Oscillococcinum® for preventing and treating influenza and influenza-like illness // Cochrane Database of Systematic Reviews. 2015. № 1. Art. № CD001957.

Pakpoor J. Homeopathy is not an effective treatment for any health condition, report concludes // 2015. Vol. 350. № 8000, h1478.

Носырев И. Гомеопатия как искусство и выгодное дело // Коммерсантъ Деньги. 07.11.2016. №.44. C. 24.

Kim S., Cha J. M., Lee C. H., Shin H. P., Park J. J., Joo K. R., Lee J. I. et al. Rectal perforation due to benign stricture caused by rectal burns associated with hot coffee enemas // Endoscopy. 2012. Vol. 44. Suppl 2. UCTN: E32–3.

Shils M. E., Hermann M. G. Unproved dietary claims in the treatment of patients with cancer // Bulletin of the New York Academy of Medicine. 1982. April. Vol. 58. № 3. P. 323–340.

Eisele J. W., Reay D. T. Deaths related to coffee enemas // JAMA. 1980. Vol. 244. № 14. P. 1608–1609.

Margolin K. A., Green M. R. Polymicrobial enteric septicemia from coffee enemas // The Western journal of medicine. 1984. March. Vol. 140. № 3. P. 460.

Bogdanich W. Chinese chemicals flow unchecked onto world drug market // The New York Times. 2007. October 31.

Yang D. L. Regulatory learning and its discontents in China: promise and tragedy at the state food and drug administration / Gillespie J., Peerenboom R. (eds.) Pushing Back Globalization. Routledge, 2009.

Patwardhan B., Warude D., Pushpangadan P., Bhatt N. Ayurveda and traditional Chinese medicine: a comparative overview // Evidence-based complementary and alternative medicine. 2005. December. Vol. 2. № 4. P. 465–473.

Deadman P., Al-Khafaji M. Some acupuncture points which treat disorders of blood // Journal of Chinese Medicine. 1998. January. № 56. P. 5–18.

Rudic J. S., Poropat G., Krstic M. N., Bjelakovic G., Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis // Cochrane Database of Systematic Reviews. 2012. № 12. Art. № CD000551.

Vickers A., Goyal N., Harland R., Rees R. Do certain countries produce only positive results? A systematic review of controlled trials // Controlled clinical trials. 1998. April. Vol. 19. № 2. P. 159–166.

Colquhoun D., Novella S. P. Acupuncture is theatrical placebo // Anesthesia and analgesia. 2013. June. Vol.116. № 6. P. 1360–1363.

Topping A. Chinese use acupuncture anesthetic in heart surgery // The New York Times. 1971. May 24.

Ernst E., Lee M. S., Choi T. Y. Acupuncture: does it alleviate pain and are there serious risks? A review of reviews // Pain. 2011. April. Vol. 152. № 4. P. 755–764.

Deare J. C., Zheng Z., Xue C. C. L., Liu J. P., Shang J., Scott S. W., Littlejohn G. Acupuncture for treating fibromyalgia // Cochrane Database of Systematic Reviews. 2013. № 5. Art. № CD007070.

Manheimer E., Cheng K., Linde K., Lao L., Yoo J., Wieland S. et al. Acupuncture for peripheral joint osteoarthritis // Cochrane Database of Systematic Reviews. 2010. January 20. № 1. Art. № CD001977.

Madsen M. V., Gøtzsche P. C. Acupuncture treatment for pain: systematic review of randomised clinical trials with acupuncture, placebo acupuncture, and no acupuncture groups // BMJ. 2009. Vol. 338. № 7690, a3115.

Linde K., Allais G., Brinkhaus B., Manheimer E., Vickers A., White A. R. Acupuncture for migraine prophylaxis // Cochrane Database of Systematic Reviews. 2009. № 1. Art. № CD001218.

Cherkin D. C., Sherman K. J., Avins A. L. et al. A randomized trial comparing acupuncture, simulated acupuncture, and usual care for chronic low back pain // Archives of internal medicine. 2009. Vol. 169. № 9. P. 858–866.

Suarez-Almazor M. E., Looney C., Liu Y., Cox V., Pietz K. et al. A randomized controlled trial of acupuncture for osteoarthritis of the knee: effects of patient-provider communication // Arthritis care & research. 2010. September. Vol. 62. № 9. P. 1229–1236.

Dincer F., Linde K. Sham interventions in randomized clinical trials of acupuncture – a review // Complementary Therapies in Medicine. 2003. December. Vol. 11. № 4. P. 235–242.

Byard R. W., Musgrave I., Maker G., Bunce M. What risks do herbal products pose to the Australian community? // The Medical journal of Australia. 2017. Vol. 206. № 2. P. 86–90.

Ernst E. Toxic heavy metals and undeclared drugs in Asian herbal medicines // Trends in Pharmacological Sciences. 2002. March 1. Vol. 23. № 3. P. 136–139.

Pittler M. H., Ernst E. Systematic review: hepatotoxic events associated with herbal medicinal products // Alimentary pharmacology & therapeutics. 2003. Vol. 18. № 5. P. 451–471.

Tanaka A., Nishida R., Yoshida T., Koshikawa M., Goto M., Kuwahara T. Outbreak of Chinese herb nephropathy in Japan: are there any differences from Belgium? // Internal medicine (Tokyo, Japan). 2001. April. Vol. 40. № 4. P. 296–300.

Zhang D., Yin P., Freemantle N., Jordan R., Zhong N., Cheng K. K. An assessment of the quality of randomised controlled trials conducted in China // Trials. 2008. April. Vol. 9. P. 22.

Gang Wang, Bing Mao, Ze-Yu Xiong, Tao Fan, Xiao-Dong Chen et al. The quality of reporting of randomized controlled trials of traditional Chinese medicine: a survey of 13 randomly selected journals from mainland China // Clinical Therapeutics. 2007. Vol. 29. № 7. P. 1456–1467.

Astin J. A. Why patients use alternative medicine: results of a national study // JAMA. 1998. Vol. 279. № 19. P. 1548–1553.

Култер К. P. Портреты гомеопатических препаратов. M.: Гомеопатическая медицина, 2004.

Naidu K. A. Vitamin C in human health and disease is still a mystery? An overview // Nutrition Journal. 2003. Vol. 2. P. 7.

Pauling L. Are recommended daily allowances for vitamin C adequate? // PNAS. 1974. November. Vol. 71. № 11. P. 4442–4446.

Offit P. The vitamin myth: Why we think we need supplements // The Atlantic. 2013. July 19.

Anderson T. W. Reid D. B. W., Beaton G. H. Vitamin C and the common cold: a double-blind trial // Canadian Medical Association Journal. 1972. Vol. 107. № 6. P. 503–508.

Anderson T. W., Stiranyi G., Beaton G. H. The effect on winter illness of large doses of vitamin C // Canadian Medical Association Journal. 1974. Vol. 111. P. 31–36.

Anderson T. W. Large-scale trials of vitamin C // Annals of the New York Academy of Sciences. 1975. Vol. 258. P. 498–504.

Anderson T. W., Beaton G. H., Corey P., Spero L. Winter illness and vitamin C: the effect of relatively low doses // Canadian Medical Association Journal. 1975. Vol. 112. № 7. P. 823–826.

Cameron E., Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer // Proceedings of the National Academy of Sciences of the United States of America. 1976. October. Vol. 73. № 10. P. 3685–3689.

Hemilä H., Chalker E. Vitamin C for preventing and treating the common cold // Cochrane Database of Systematic Reviews. 2013. № 1. Art. № CD000980.

Iacopetta K., Collins-Praino L. E., Buisman-Pijlman F. T. A., Liu J. et al. Are the protective benefits of vitamin D in neurodegenerative disease dependent on route of administration? A systematic review // Nutritional Neuroscience. 2018. July. Vol. 9. P. 1–30.

Allan G. M., Cranston L., Lindblad A., McCormack J., Kolber M. R. et al. Vitamin D: A narrative review examining the evidence for ten beliefs // Journal of General Internal Medicine. 2016. July. Vol. 31. № 7. P. 780–791.

Bjelakovic G., Gluud L., Nikolova D., Whitfield K., Wetterslev J. et al. Vitamin D supplementation for prevention of mortality in adults // Cochrane Database of Systematic Reviews. 2014. № 1. Art. № CD007470.

Macpherson H., Pipingas A., Pase M. P. Multivitamin-multimineral supplementation and mortality: a meta-analysis of randomized controlled trials // The American journal of clinical nutrition. 2013. February. Vol. 97. № 2. P. 437–444.

The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. The Effect of Vitamin E and Beta Carotene on the Incidence of Lung Cancer and Other Cancers in Male Smokers // The New England Journal of Medicine. 1994. April 14. Vol. 330. P. 1029–1035.

Bjelakovic G., Nikolova D., Simonetti R. G., Gluud C. Antioxidant supplements for preventing gastrointestinal cancers // Cochrane Database of Systematic Reviews. 2008. July. Vol. 16. № 3, CD004183.

Omenn G. S., M. D., Goodman G. E., Thornquist M. D., Balmes J., Cullen M. R. et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease // The New England Journal of Medicine. 1996. May 2. Vol. 334. P. 1150–1155.

Miller E. R., Pastor-Barriuso R., Dalal D., Riemersma R. A., Appel L. J. et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality // Annals of Internal Medicine. 2005. Vol. 142. № 1. P. 37–46.

Dyerberg J. Coronary heart disease in Greenland Inuit: a paradox. Implications for western diet patterns // Arctic medical research. 1989. April. Vol. 48. № 2. P. 47–54.

Abdelhamid A. S., Brown T. J., Brainard J. S., Biswas P., Thorpe G. C. et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease // Cochrane Database of Systematic Reviews. 2018. № 7. Art. № CD003177.

Kwak S. M., Myung S. K., Lee Y. J., Seo H. G. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials // Archives of internal medicine. 2012. May 14. Vol. 172. № 9. P. 686–694.

Rizos E. C., Ntzani E. E., Bika E., Kostapanos M. S., Elisaf M. S. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis // JAMA. 2012. September 12. Vol. 308. № 10. P. 1024–1033.

Aung T., Halsey J., Kromhout D. et al. Associations of Omega-3 fatty acid supplement use with cardiovascular disease risks. Meta-analysis of 10 trials involving 77 917 individuals // JAMA Cardiology. 2018. Vol. 3. № 3. P. 225–233.

Bhatt D. L., Steg P. G., Miller M., Brinton E. A., Jacobson T. A. et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia // The New England Journal of Medicine. 2019. January 3. Vol. 380. P. 11–22.

Manson J. E., Cook N. R., I – Min Lee, Christen W., Bassuk S. S. et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer // The New England Journal of Medicine. 2019. January 3. Vol. 380. P. 23–32.

Carroll A. E. Given Their Potential for Harm, It’s Time to Focus on the Safety of Supplements // JAMA. 2018. Vol. 320. № 13. P. 1306–1307.

Newmaster S. G., Grguric M., Shanmughanandhan D., Ramalingam S., Ragupathy S. DNA barcoding detects contamination and substitution in North American herbal products // BMC medicine. 2013. Vol. 11. № 1. P. 222.

Harmon K. Herbal supplement sellers dispense dangerous advice, false claims // Scientific American. 2010. May 28.

Geller A. I., Shehab N., Weidle N. J., Lovegrove M. C., Wolpert B. J. et al. Emergency department visits for adverse events related to dietary supplements // The New England Journal of Medicine. 2015. October 15. Vol. 373. P. 1531–1540.

Gregory P. Availability of DMAA supplements despite US food and drug administration action // JAMA Internal Medicine. 2013. Vol. 173. № 2. P. 164–165.

Zhang Y., Woods R. M., Breitbach Z. S., Armstrong D. W. 1,3-Dimethylamylamine (DMAA) in supplements and geranium products: natural or synthetic? // Drug Testing and Analysis. 2012. Vol. 4. P. 986–990.

Lindeboom G. A. The story of a blood transfusion to a pope // Journal of the History of Medicine and Allied Sciences. 1954. October 1. Vol. 9. № 4. P. 455–459.

Kaiser J. Blood from young people does little to reverse Alzheimer’s in first test // Science. 2017. November 1.

Cooper D. K. C. A brief history of cross-species organ transplantation // Proceedings (Baylor University. Medical Center). 2012. January. Vol. 25. № 1. P. 49–57.

Bajic P., Selman S. H., Rees M. A. Voronoff to virion: 1920s testis transplantation and AIDS // Xenotransplantation. 2012. November-December. Vol. 19. № 6. P. 337–341.

Setchell B. P. The testis and tissue transplantation: historical aspects // Journal of reproductive immunology. 1990. August. Vol. 18. № 1. P. 1–8.

Wang H., Zhao Y., Ezcurra M., Benedetto A., Gilliat A. F., Hellberg J., Ren Z. et al. A parthenogenetic quasi-program causes teratoma-like tumors during aging in wild-type C. elegans // npj Aging and Mechanisms of Disease. 2018. Vol. 4. Art. № 6.

Cheetham T. C., An J., Jacobsen S. J. et al. Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency // JAMA Internal Medicine. 2017. Vol. 177. № 4. P. 491–499.

Basaria S., Coviello A. D. Travison T. G., Storer T. W., Farwell W. R. et al. Adverse events associated with testosterone administration // The New England Journal of Medicine. 2010. July 8. Vol. 363. № 2. P. 109–122.

Bhasin S., Cunningham G. R., Hayes F. J., Matsumoto A. M., Snyder P. J. et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline // The Journal of Clinical Endocrinology & Metabolism. 2006. June 1. Vol. 91. № 6. P. 1995–2010.

Rudman D., Feller A. G., Nograj H. S., et al. Effects of human growth hormone in men over 60 years old // The New England Journal of Medicine. 1990. Vol. 323. № 1. P. 1–6.

Swerdlow A. J., Cooke R., Beckers D., Borgström B., Butler G. et al. Cancer risks in patients treated with growth hormone in childhood: the SAGhE European cohort study // The Journal of clinical endocrinology and metabolism. 2017. May 1. Vol. 102. № 5. P. 1661–1672.

Robida-Stubbs S., Glover-Cutter K., Lamming D. W., Mizunuma M. et al. TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO // Cell metabolism. 2012. May 2. Vol. 15. № 5. P. 713–724.

Bhullar K. S., Hubbard B. P. Lifespan and healthspan extension by resveratrol // Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease. 2015. June. Vol. 1852. № 6. P. 1209–1218.

Rousakis A., Vlassis A., Vlanti A., Patera S., Thireos G., Syntichaki P. The general control nonderepressible-2 kinase mediates stress response and longevity induced by target of rapamycin inactivation in Caenorhabditis elegans // Aging Cell. 2013. Vol. 12. № 5. P. 742–751.

Baur J. A., Pearson K. J., Price N. L., Jamieson H. A., Lerin C., Kalra A. et al. Resveratrol improves health and survival of mice on a high-calorie diet // Nature. 2006. November 16. Vol. 444. № 7117. P. 337–342.

Pearson K. J., Baur J. A., Lewis K. N., Peshkin L., Price N. L., Labinskyy N. et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span // Cell metabolism. 2008. August. Vol. 8. № 2. P. 157–168.

Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the ‘French paradox’? // European Journal of Endocrinology. 1998. June. Vol. 138. № 6. P. 619–620.

Goldberg D. M., Yan J., Soleas G. J. Absorption of three wine-related polyphenols in three different matrices by healthy subjects // Clinical biochemistry. 2003. February. Vol. 36. № 1. P. 79–87.

Law M., Wald N. Why heart disease mortality is low in France: the time lag explanation // BMJ. 1999. May 29. Vol. 318. № 7196. P. 1471–1480.

Vang O. What is new for resveratrol? Is a new set of recommendations necessary? // Annals of the New York Academy of Sciences. 2013. July. Vol. 1290. № 1. P. 1–11.

Vaziri H., Dragowska W., Allsopp R. C., Thomas T. E., Harley C. B., Lansdorp P. M. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age // PNAS. 1994. October 11. Vol. 91. № 21. P. 9857–9860.

Jodczyk S., Fergusson D. M., Horwood L. J., Pearson J. F., Kennedy M. A. No association between mean telomere length and life stress observed in a 30 year birth cohort // PLoS One. 2014. Vol. 9. № 5, e97102.

Chae D. H., Nuru-Jeter A. M., Adler N. E., Brody G. H., Lin J., Blackburn E. H., Epel E. S. Discrimination, racial bias, and telomere length in African-American men // American journal of preventive medicine. 2014. February. Vol. 46. № 2. P. 103–111.

Jaskelioff M., Muller F. L., Paik J.-H., Thomas E., Jiang S., Adams A. et al. Telomerase reactivation reverses tissue degeneration in aged telomerase deficient mice // Nature. 2011. January 6. Vol. 469. № 7328. P. 102–106.

Sprouse A. A., Steding C. E., Herbert B.-S. Pharmaceutical regulation of telomerase and its clinical potential // Journal of cellular and molecular medicine. 2012. January. Vol. 16. № 1. P. 1–7.

Sanders J. L., Newman A. B. Telomere length in epidemiology: a biomarker of aging, age-related disease, both, or neither? // Epidemiologic Reviews. 2013. January 1. Vol. 35. № 1. P. 112–131.